

**New York University**  
**Consolidated Financial Statements and**  
**Supplemental Information**  
**August 31, 2024 and 2023**

**New York University**  
**Index**  
**August 31, 2024 and 2023**

---

	<b>Page(s)</b>
<b>Report of Independent Auditors .....</b>	<b>1–2</b>
<b>Consolidated Financial Statements</b>	
Balance Sheets .....	3
Statements of Activities .....	4
Statements of Cash Flows .....	5
Notes to Financial Statements .....	6–42
<b>Appendix A - Supplemental Information</b>	
Consolidating Supplemental Schedules .....	43–52
Note to Consolidating Supplemental Schedules .....	53



## **Report of Independent Auditors**

To the Board of Trustees of New York University

### ***Opinion***

We have audited the accompanying consolidated financial statements of New York University and its subsidiaries (the "Company"), which comprise the consolidated balance sheets as of August 31, 2024 and 2023, and the related consolidated statements of activities and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of August 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

### ***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### ***Responsibilities of Management for the Consolidated Financial Statements***

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

### ***Auditors' Responsibilities for the Audit of the Consolidated Financial Statements***

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

#### ***Supplemental Information***

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The accompanying consolidating balance sheets – summary, consolidating balance sheets – detail, consolidating statements of activities – summary, consolidating statements of activities – detail and consolidating statements of cash flows – summary as of and for the years ended August 31, 2024 and 2023 included in Appendix A (the “supplemental information”) are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. The consolidating information is not intended to present, and we do not express an opinion on, the financial position, changes in net assets and cash flows of the individual companies. The supplemental information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The supplemental information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

*PricewaterhouseCoopers LLP*

New York, New York  
December 12, 2024

**New York University**  
**Consolidated Balance Sheets**  
**August 31, 2024 and 2023**

*(in thousands of dollars)*

	<b>2024</b>	<b>2023</b>
<b>Assets</b>		
Cash and cash equivalents	\$ 2,847,533	\$ 1,390,097
Short-term investments (Note 5)	825,459	2,373,694
Accounts and loans receivable, net (Note 6)	714,796	733,080
Patient accounts receivable, net (Note 4)	1,542,506	1,230,323
Contributions receivable, net (Note 7)	655,476	694,649
Other assets (Note 8)	1,388,010	1,239,750
Deposits with trustees (Note 9)	114,699	344,368
Long-term investments (Note 5)	7,841,964	6,812,105
Operating right-of-use assets (Note 11)	2,056,573	2,040,225
Assets held for professional liabilities (Note 13)	1,302,614	1,096,600
Land, buildings, and equipment, net (Note 10)	15,195,369	14,519,779
Total assets	<u>\$ 34,484,999</u>	<u>\$ 32,474,670</u>
<b>Liabilities and Net Assets</b>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$ 2,730,882	\$ 2,575,692
Deferred revenue	1,304,408	1,337,755
Operating lease liability (Note 11)	2,263,516	2,226,362
Professional liabilities (Note 13)	1,032,601	967,037
Debt and other obligations (Note 12)	9,659,685	9,668,268
Funds held for others (Notes 6 and 8)	690,957	552,544
Accrued benefit obligation (Note 14)	231,847	229,087
Accrued postretirement obligation (Note 14)	479,954	456,817
Asset retirement obligation	323,915	301,943
Total liabilities	<u>18,717,765</u>	<u>18,315,505</u>
<b>Net assets</b>		
Without donor restrictions	10,174,080	9,123,054
With donor restrictions (Note 17)	5,593,154	5,036,111
Total net assets	<u>15,767,234</u>	<u>14,159,165</u>
Total liabilities and net assets	<u>\$ 34,484,999</u>	<u>\$ 32,474,670</u>

The accompanying notes are an integral part of these consolidated financial statements.

**New York University**  
**Consolidated Statements of Activities**  
**Years Ended August 31, 2024 and 2023**

(in thousands of dollars)

	2024	2023
<b>Changes in net assets without donor restrictions</b>		
Operating revenues		
Tuition and fees (net of financial aid awards of \$926,657 and \$897,928)	\$ 2,566,849	\$ 2,511,289
Grants and contracts (Note 2)	1,584,349	1,522,489
Patient care (Note 4)	11,114,214	9,831,332
Pharmacy revenue	870,909	686,810
Hospital affiliations (Note 15)	520,663	479,934
Insurance premiums earned	27,692	27,555
Contributions	98,289	77,437
Endowment distribution (Note 5)	253,761	228,903
Return on short-term investments (Note 5)	219,075	164,359
Auxiliary enterprises (net of financial aid awards of \$94,505 and \$91,060)	451,604	417,367
Program fees and other	327,812	315,764
Net assets released from restrictions	206,457	165,296
Total operating revenues	18,241,674	16,428,535
Expenses (Note 16)		
Salaries and fringe	10,698,797	9,453,003
Medical and pharmaceutical costs	2,115,223	1,759,994
Professional services	926,174	808,704
Facilities costs	1,018,449	947,386
Fees, insurance and taxes	315,305	301,515
Depreciation and amortization	1,128,846	1,012,445
Interest	374,220	372,396
Other	1,269,004	1,255,265
Total expenses	17,846,018	15,910,708
Excess of operating revenues over expenses	395,656	517,827
Nonoperating activities		
Investment return (Note 5)	589,037	329,835
Appropriation of endowment distribution (Note 5)	(84,213)	(73,286)
Pension and postretirement nonservice costs (Note 14)	14,589	18,870
Changes in pension and postretirement obligations (Note 14)	(58,634)	229,863
Net assets released from restrictions for capital	38,726	103,597
Proceeds from settlements (Note 18)	122,246	508,000
Other	33,619	(892)
Increase in net assets without donor restrictions	1,051,026	1,633,814
<b>Changes in net assets with donor restrictions</b>		
Contributions	381,858	451,952
Investment return (Note 5)	591,731	273,997
Appropriation of endowment distribution (Note 5)	(169,548)	(155,617)
Other	(1,815)	(2,401)
Net assets released from restrictions	(245,183)	(268,893)
Increase in net assets with donor restrictions	557,043	299,038
Increase in net assets	\$ 1,608,069	\$ 1,932,852

The accompanying notes are an integral part of these consolidated financial statements.

# New York University

## Consolidated Statements of Cash Flows

### Years Ended August 31, 2024 and 2023

(in thousands of dollars)

	2024	2023
<b>Cash flows from operating activities</b>		
Change in net assets	\$ 1,608,069	\$ 1,932,852
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Depreciation and amortization	1,128,846	1,012,445
Loss (gain) on sale or disposal of land, buildings and equipment	159	(7,349)
Net gain on investments, deposits with trustees, and split-interest agreements	(1,110,019)	(534,863)
Bad debt expense	91,979	7,962
Pension and postretirement obligation change	58,634	(229,863)
Contributions received for permanent investment and capital	(160,011)	(130,768)
Proceeds from disaster recovery award for hazard mitigation and capital	-	(13,264)
Amortization of operating right-of-use assets	273,981	272,806
Changes in operating assets and liabilities		
Decrease in accounts and loans receivable, net	9,485	7,434
Increase in patient accounts receivable	(312,183)	(14,603)
Increase in contributions receivable	(44,007)	(73,732)
Increase in other assets	(36,966)	(86,812)
Decrease in asset retirement obligation	(4,038)	(1,326)
Increase in accounts payable and accrued expenses	97,121	9,875
Decrease in operating lease liability	(253,175)	(252,425)
Increase in professional liabilities	65,564	49,809
(Decrease) increase in deferred revenue	(33,347)	37,890
Decrease in accrued benefit obligation	(44,039)	(15,342)
(Decrease) increase in accrued postretirement obligation	(2,833)	3,771
Net cash provided by operating activities	<u>1,333,220</u>	<u>1,974,497</u>
<b>Cash flows from investing activities</b>		
Purchases of investments	(5,928,516)	(5,091,772)
Sales and maturities of investments	7,283,376	3,128,453
Drawdowns of unexpended bond proceeds	160,602	121,034
Proceeds from sale of building	6,000	-
Additions to land, buildings, and equipment	(1,724,357)	(1,651,615)
Net cash used in investing activities	<u>(202,895)</u>	<u>(3,493,900)</u>
<b>Cash flows from financing activities</b>		
Contributions received for permanent investment and capital	160,011	130,768
Proceeds from disaster recovery award for hazard mitigation and capital	-	13,264
Proceeds from short-term borrowings	355,200	-
Proceeds from finance lease incentives	4,408	15,077
Principal payments on long-term borrowings and finance leases	(225,521)	(221,884)
Line of credit repayments	(93,800)	-
Decrease in funds held for others	(3,327)	(19,781)
Net cash provided by (used in) financing activities	<u>196,971</u>	<u>(82,556)</u>
Net increase (decrease) in cash, cash equivalents and restricted cash	<u>1,327,296</u>	<u>(1,601,959)</u>
<b>Cash, cash equivalents and restricted cash</b>		
Beginning of year	<u>1,771,367</u>	<u>3,373,326</u>
End of year	<u>\$ 3,098,663</u>	<u>\$ 1,771,367</u>
<b>Supplemental disclosure of cash flow information</b>		
Interest paid	\$ 395,329	\$ 390,054
Change in noncash acquisitions of land, buildings, and equipment	72,819	147,455
Right-of-use assets obtained		
In exchange for new operating lease obligations	\$ 307,722	\$ 205,015
In exchange for new finance lease obligations	80,883	233,624

The accompanying notes are an integral part of these consolidated financial statements.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

---

*(in thousands of dollars)*

#### 1. Description of New York University

Founded in 1831, New York University (NYU) is a private institution of higher education, research, and patient care located primarily in New York City. NYU is recognized both nationally and internationally as a leader in scholarship and is a member of the distinguished Association of American Universities.

The consolidated reporting entities for NYU consist of the University and NYU Langone Health, which represents the activities of NYU Langone Health System (Health System) and its two medical schools: the NYU Robert I. Grossman School of Medicine (NYUGSoM) and NYU Grossman Long Island School of Medicine (collectively the NYU Schools of Medicine).

##### **The University**

The University includes the following colleges, schools, divisions, institutes and portal campuses, each with its own traditions, programs and faculty, listed in order of founding date: the College of Arts and Science, School of Law, NYUGSoM (reported as a part of NYU Langone Health), College of Dentistry, Graduate School of Arts and Science, Steinhardt School of Culture, Education and Human Development, Leonard N. Stern School of Business, Courant Institute of Mathematical Sciences, School of Professional Studies, Institute of Fine Arts, Robert F. Wagner Graduate School of Public Service, Silver School of Social Work, Tisch School of the Arts, Gallatin School of Individualized Study, NYU Abu Dhabi, Tandon School of Engineering (formerly Polytechnic University founded in 1854), Rory Meyers College of Nursing, Institute for the Study of the Ancient World, School of Global Public Health, and NYU Grossman Long Island School of Medicine (reported as part of NYU Langone Health). The University also operates academic program sites and research programs in other parts of the United States and abroad.

In addition to the above colleges, schools, divisions, institutes and portal campuses, NYU has a degree-granting campus in Shanghai, People's Republic of China, NYU Shanghai, which operates as a joint venture with East China Normal University. The New York-based activities of NYU Shanghai are reported in the University's consolidated balance sheets and consolidated statements of activities.

##### **NYU Langone Health**

The Health System is the sole corporate member of NYU Langone Hospitals, which is a quaternary care teaching hospital that operates five inpatient acute care facilities and over 40 ambulatory facilities in Manhattan, Brooklyn, and Long Island. The 813-bed inpatient facilities in Manhattan are comprised of the Kimmel Pavilion (which also houses the Hassenfeld Children's Hospital) and Tisch Hospital. The NYU Langone Orthopedic Hospital, also located in Manhattan, is a 225-bed facility specializing in orthopedic, neurologic, and rheumatologic services. NYU Langone Hospital-Brooklyn is a 444-bed facility in the Sunset Park section of Brooklyn. NYU Langone Hospital-Long Island is a 591-bed acute care facility located in Mineola, New York. Ambulatory facilities include the Laura and Isaac Perlmutter Cancer Center, a comprehensive cancer and ambulatory care center, as well as the Joseph S. and Diane H. Steinberg Ambulatory Care Center, in the Cobble Hill section of Brooklyn, which includes a free-standing emergency department, amongst others.

On March 1, 2022, pursuant to the terms of an affiliation agreement (the Affiliation Agreement), the Health System became the sole corporate member of Long Island Community Hospital at NYU Langone Health (LICH), an acute care hospital licensed to operate 306 beds located in Suffolk County, New York. The Affiliation Agreement provides that after a three-year period and satisfaction of various closing conditions, LICH will merge with and into NYU Langone Hospitals,



# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

---

(in thousands of dollars)

unless an earlier (or in certain limited circumstances, later) time is determined by the Health System, in consultation with LICH.

NYUGSoM employs approximately 3,900 faculty physicians (the Faculty Group Practice) who render patient care in more than 300 practice locations primarily in the New York City region, and two practice locations in Delray Beach and West Palm Beach, Florida. These physicians constitute the principal clinical service providers for NYU Langone Hospitals' facilities.

NYU Langone Hospitals is the sole corporate member of CCC550 Insurance, SCC. (CCC550), which provides the hospitals' professional and general liability insurance, as well as insurance to physicians employed by the NYUGSoM and other non-employed physicians. CCC550 is subject to taxation in accordance with Section 29 of the Exempt Insurance Act in Barbados.

## 2. Summary of Significant Accounting Policies

### Basis of Presentation

The consolidated financial statements of NYU have, in all material respects, been prepared on an accrual basis in accordance with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements include the accounts of NYU, as well as its separately incorporated affiliates. NYU and, generally, all of its affiliates are exempt from federal income taxes under the provisions of Section 501(c)(3) of the Internal Revenue Code.

NYU prepares its consolidated financial statements in accordance with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 958, *Not for Profit Entities*. This standard focuses on the entity as a whole and requires classification of net assets as determined by the existence or absence of restrictions placed on the assets' uses by donors or by provision of law. A description of the net asset classifications follows:

*Without Donor Restrictions:* Net assets of NYU that are used to carry out its missions of education, research and patient care which are not subject to donor restrictions.

*With Donor Restrictions:* Net assets subject to donor-imposed restrictions that will be met either by the actions of NYU or the passage of time. Items that are included in donor restricted net assets are gifts for which donor-imposed restrictions have not been met in the year of receipt; endowments, annuities, and life income gifts; pledges; investment return on donor restricted endowment funds; and endowments where the principal may be expended upon the passage of a stated period of time. Expirations of restrictions on net assets with donor restrictions are reported as net assets released from restrictions in the consolidated statements of activities. In addition, NYU has elected the simultaneous release option for contributions that are also subject to purpose restrictions.

### Activities

Revenues and expenses related to conducting programmatic activities and provision of services by NYU are classified as operating in the consolidated statements of activities. Investment return relating to board-designated endowment funds and the related endowment appropriation, as well as nonservice changes in pension and postretirement obligations, proceeds from settlements

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

(Note 18), and other activity that is not part of NYU's core activities are classified as nonoperating in the consolidated statements of activities.

**Tuition and Fees**

Tuition and fees are derived from degree-granting programs as well as executive and continuing education programs. Tuition and fee revenue is recognized within the fiscal year in which the related educational services are provided as the performance obligation is satisfied. Tuition and fee receipts received in advance of a semester are recorded as deferred revenue. Financial aid, in the form of scholarships and grants, including amounts funded by the endowment, research funds, and gifts reduces the published price of tuition for students receiving such aid. As such, financial aid is referred to as a tuition discount and represents the difference between the stated charge for tuition and fees and the amount that is billed to the student and/or third parties making payments on behalf of the student. Tuition and fees are reported net of financial aid on the consolidated statements of activities.

**Auxiliary Enterprises**

Auxiliary enterprises are self-supporting activities that furnish goods or services to students, faculty, staff, or incidentally to the general public, and charge a fee directly related to, although not necessarily equal to, the cost of the goods or services. Auxiliary enterprises include student housing and dining, real estate rental income, student health, and other similar activities. Student housing and dining services are delivered over the academic terms and revenues are recognized ratably as the performance obligation is satisfied. Student housing and dining services are presented net of financial aid on the consolidated statements of activities.

**Grants and Contracts**

NYU receives funding for sponsored programs from various government agencies, foundations, and corporations. The funding may represent a reciprocal transaction in exchange for an equivalent benefit in return, or it may be a nonreciprocal nonexchange transaction in which the funding provided is for the benefit of NYU, the funding organization's mission, or the public at large.

Revenues from nonexchange transactions may be subject to conditions, in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments). NYU's grants and contracts are primarily conditional nonexchange transactions and revenues are recognized when expenses are incurred. Unspent conditional contributions from grants and contracts total \$1,094,266 and \$1,081,800 at August 31, 2024 and 2023, respectively. Revenues from unconditional nonexchange transactions are recognized in the period awarded.

During the years ended August 31, 2024 and 2023, grants and contracts revenue recognized from U.S. governmental sources totaled \$842,108 and \$805,568, respectively. Such sponsored grants and contracts generally provide for the recovery of indirect costs supporting these activities. Indirect costs, included in grants and contracts revenues, are recovered at rates established in advance by NYU through negotiations with the U.S. federal government and other private sponsors and totaled \$255,140 and \$239,871, respectively.

**Contributions**

Contributions, including unconditional promises to give, are recognized as revenue in the period received at their fair value. Contributions receivable are reported at their discounted present value, using an estimated interest rate for the year in which the promise was received and considering market and credit risk as applicable (4.16%-4.51% in 2024 and 4.48%-4.84% in 2023).

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

Amortization of the discount is recorded as additional contribution revenue. Allowances are recorded for estimated uncollectible contributions based upon management's judgment and analysis of the creditworthiness of the donors, past collection experience and other relevant factors.

**Fair Value Measurements**

Authoritative guidance of fair value measurements, ASC 820, *Fair Value Measurements*, establishes a hierarchy of valuation methodologies based on the extent to which asset valuations are observable in the marketplace.

The following describes the hierarchy of methodologies used to measure fair value of investments:

Fair value for Level 1 is based on unadjusted quoted prices in actively traded markets that NYU has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets.

Fair value for Level 2 is based on quoted prices for instruments similar to those held by NYU in actively traded markets, quoted prices for identical instruments held by NYU in markets that are not actively traded and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data. Inputs are obtained from various sources including market participants, dealers and brokers.

Fair value for Level 3 is based on valuation techniques used to assess prices that are unobservable as the assets trade infrequently or not at all.

Investments for which fair value is measured at net asset value (NAV) per share as a practical expedient consist primarily of NYU's ownership in alternative investments (principally limited partnership interests in public equity, hedge funds, credit, real assets, private equity, real estate, and other similar funds). The NAV of the securities held by limited partnerships that do not have readily determinable fair values are determined by the general partner and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investment securities, the fair value is determined by the general partner taking into consideration, among other things, the cost of the securities, prices of recent significant placements of securities of the same issuer and subsequent developments concerning the companies to which the securities relate. NYU has performed due diligence on these investments and believes the reported NAV as a practical expedient is an appropriate measure of fair value as of August 31, 2024 and 2023.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while NYU believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

**Cash and Cash Equivalents**

Cash and cash equivalents include cash and all highly-liquid debt instruments with original maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates fair value due to the short-term maturity of the instruments. NYU maintains its deposits with high credit quality financial institutions, with balances that exceed

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

federal depository insurance limits. Management does not believe the credit risk related to these deposits is significant. All short-term, highly liquid investments, which would otherwise qualify as cash equivalents that are included in NYU's investment pool within long-term investments, are treated as investments and are therefore excluded from cash and cash equivalents in the consolidated statements of cash flows.

The following table provides a reconciliation of cash and cash equivalents reported within the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows at August 31, 2024 and 2023:

	<b>2024</b>	<b>2023</b>
Cash and cash equivalents	\$ 2,847,533	\$ 1,390,097
Cash in short-term investments	-	199,459
Cash in long-term investment pool (Note 5)	142,197	142,250
Cash in other long-term investments (Note 5)	2,498	1,952
Cash in deposits with trustees (Note 9)	56,183	8,774
Cash in assets held for professional liabilities (Note 13)	50,252	28,835
	<u>\$ 3,098,663</u>	<u>\$ 1,771,367</u>
Cash, cash equivalents and restricted cash		

**Investments**

Short-term investments consist primarily of money market funds and U.S. Treasury bills with original maturities greater than three months and up to twelve months when purchased. Long-term investments consist primarily of public equity securities, fixed income securities, and assets held in the NYU investment pool (Note 5).

**Land, Buildings, and Equipment**

Land, buildings, and equipment are carried at their acquisition or construction cost. If donated, these assets are recorded at their fair value on the date of the gift. Buildings and equipment are depreciated over their estimated useful lives (buildings and building improvements 10-60 years, equipment 3-20 years) using the straight-line method. Repairs and maintenance expenditures are expensed when incurred.

**Leases**

NYU leases certain academic spaces, medical offices, administrative offices, and equipment under finance and operating leases. Operating lease right-of-use (ROU) assets and operating lease obligations are recognized based on the present value of lease payments over the lease term, where the initial term of the lease exceeds 12 months. NYU uses its incremental borrowing rate to calculate the present value of lease payments because the leases do not have a readily determinable implicit discount rate. As a practical expedient, NYU elected to include both lease and nonlease components in the calculation of the operating lease ROU asset and operating lease obligation. Variable lease payments are excluded for purposes of calculating the operating ROU asset and operating lease obligation unless the variable lease payments depend on an index or rate or are in substance fixed payments. Lease payments related to periods subject to renewal options are also excluded for purposes of calculating the operating ROU asset and operating lease obligation unless NYU is reasonably certain to exercise the option to extend the lease.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

---

(in thousands of dollars)

Lease expense for operating leases is recognized on a straight-line basis over the term of the lease.

#### **Collections**

The University does not assign a value to collection items. Collection items are generally held for educational purposes and consist of pieces of art. Collection items are not disposed of for financial gain or otherwise encumbered in any manner.

#### **Deferred Revenue**

Deferred revenue consists of tuition and fees and student housing and dining fees received in advance of the Fall semester as well as funding received for grants and contracts in advance of incurring the qualifying expenses.

#### **Asset Retirement Obligation**

NYU recognizes asset retirement obligations on future events, such as the abatement of asbestos and removal of lead-based paint and petroleum bulk storage tanks from buildings. The fair value of the liability for a conditional asset retirement obligation is recognized in the period in which it occurred, provided that it can be reasonably estimated. Corresponding asset retirement costs (net of accumulated depreciation) have been included in land, buildings, and equipment.

#### **Funds Held for Others**

Funds held for others consist of NYU's federal grants refundable and liabilities associated with 457(b) deferred compensation plans. Corresponding assets are included within accounts receivable (Note 6) and other assets (Note 8), respectively.

#### **Related Parties**

Transactions between NYU and any of its trustees, officers or employees are subject to NYU's conflict of interest policies, which require disclosure of conflicting interests and abstention by the conflicted persons from associated NYU decision making. NYU assesses related party transactions, including those with external organizations.

#### **Accounting Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingencies at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### **Reclassifications**

Certain amounts in the 2023 consolidated financial statements have been reclassified to conform to the current year's presentation. These reclassifications have no impact on the net assets or changes in net assets previously reported

#### **Authoritative Pronouncements Adopted**

In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, *Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments*. The new standard removes the previous requirement that a credit loss be probable of occurring for it to be recognized, and requires entities to use historical experience, current conditions, and reasonable and supportable forecasts to estimate their future expected credit losses. The standard is required

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

---

(in thousands of dollars)

to be applied using the modified retrospective approach with a cumulative-effect adjustment to net assets. This ASU is effective for fiscal years beginning after December 15, 2022. NYU adopted this standard for the year ended August 31, 2024 and adoption did not have a material impact on NYU's consolidated financial statements.

### 3. Financial Assets and Liquidity Resources

As of August 31, 2024 and 2023, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt, and capital expenditures not financed with debt, were as follows:

	2024	2023
<b>Financial assets</b>		
Cash and short-term investments	\$ 3,672,992	\$ 3,763,791
Investments available for general purposes	1,337,878	846,753
Accounts receivable, net	279,557	262,374
Grants and contracts receivable, net	178,296	213,252
Insurance premiums and recoveries receivable	6,257	8,362
Patient accounts receivable, net	1,542,506	1,230,323
Nonendowment pledge payments due within one year	90,494	97,544
Other assets	68,279	46,870
Subsequent year endowment distribution	264,280	250,526
Total financial assets available within one year	<u>7,440,539</u>	<u>6,719,795</u>
<b>Liquidity resources</b>		
Undrawn bank lines of credit and commercial paper (Note 12)	1,482,910	1,444,470
Funds functioning as endowment available for operations (Note 17)	<u>2,317,050</u>	<u>1,931,507</u>
Total liquidity resources	<u>3,799,960</u>	<u>3,375,977</u>
Total financial assets and liquidity resources available within one year	<u>\$ 11,240,499</u>	<u>\$ 10,095,772</u>

The University's cash flows have seasonal variations during the year attributable to tuition billing cycles and, at times, a concentration of contributions received at calendar year end. The University's Reserve and Liquidity Management Policy provides guidelines for calculating and reporting the global cash position on a daily basis as well as rigorous cash flow forecasting. This approach is adopted to maximize the portion of working capital funds that may remain invested. The Working Capital Fund Investment Policy (the Investment Policy) has a primary objective of aligning the maturity and liquidity profile of the working capital portfolio with the University's anticipated spending needs, while preserving the principal invested and maximizing return among a subset of approved investment grade products and providers. The Investment Policy establishes concentration limits for both investments and banking institutions. Liquidity resources are available with NYU board of trustees' approval.

As part of NYU Langone Health's liquidity management, financial assets are structured to be available as its general expenditures, liabilities and other obligations come due. In addition, NYU

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

---

(in thousands of dollars)

Langone Health may invest cash in excess of daily requirements in short-term or liquid investments.

#### 4. Patient Care Revenue and Receivable

Patient care revenue and receivables consist primarily of patient care services provided by NYU Langone Health. The University's College of Dentistry provides dental clinic services to patients as part of a student's training.

NYU Langone Health has agreements with third party payors that provide for payments at amounts different from its established rates (i.e. gross charges). Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges and per diem payments.

NYU Langone Health grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor arrangements. NYU Langone Health bills patients and third-party payers several days after the services are performed and/or the patient is discharged. Patient care revenue is recognized as performance obligations are satisfied over time based on actual charges incurred in relation to total expected charges. Generally, performance obligations over time relate to patients receiving inpatient acute care services or patients receiving services in NYU Langone Health's outpatient and ambulatory care centers. NYU Langone Health measures the performance obligation from admission into the hospital or the commencement of an outpatient or physician service to the point when it is no longer required to provide services to that patient, which is generally the time of discharge or the completion of the outpatient or physician visit.

As substantially all of its performance obligations relate to contracts with a duration of less than one year, NYU Langone Health has elected to apply the optional exemption provided in ASC 606-10-50-14(a) *Revenue from Contracts with Customers* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

NYU Langone Health determines the transaction price based on gross charges for services provided, reduced by adjustments provided to third-party payers based on contractual agreements, discounts provided to uninsured patients in accordance with NYU Langone Health's policy, and implicit concessions provided to uninsured patients.

NYU's patient accounts receivable, after contractual adjustments and implicit price concessions, is \$1,542,506 and \$1,230,323 at August 31, 2024 and 2023, respectively. NYU Langone Health estimates its contractual adjustments and implicit price concessions using a monthly standardized approach to review historical collections based on major payor classification as a practical expedient to account for patient contracts as collective groups rather than individually. Based on historical collection trends, the financial statement effects of using this practical expedient are not materially different from an individual contract approach. In addition, NYU Langone Health assesses the current state of its billing functions in order to identify any known collection or

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

reimbursement issues and assess the impact, if any, on estimates. NYU Langone Health believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably those related to obtaining the correct information in order to bill effectively for the services it provides. Subsequent changes to the estimate of transaction price are recorded as adjustments to net patient care revenue in the period of the change. Certain patient care revenues received are subject to retroactive adjustments under reimbursement agreements with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined.

NYU Langone Health has established estimates, based on information presently available, of amounts due to or from Medicare and non-Medicare payors for adjustments to current and prior year payment rates, based on industry-wide and hospital-specific data. The amounts due to third party payors included in accounts payable and accrued expenses on the consolidated balance sheets is \$184,788 and \$163,077 at August 31, 2024 and 2023, respectively. Additionally, certain payors' payment rates for various years have been appealed by NYU Langone Health. If the appeals are successful, additional income applicable to those years will be realized.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. NYU Langone Hospitals' Medicare cost reports have been audited by the Medicare fiscal intermediary through August 31, 2018. NYU Langone Hospital-Brooklyn's cost reports have been audited by the Medicare fiscal intermediary through December 31, 2015; however, final settlement is pending for 2013. NYU Langone Hospital-Long Island's Medicare cost reports have been audited by the Medicare fiscal intermediary through July 31, 2019. LICH's Medicare cost reports have been audited by the Medicare fiscal intermediary through December 31, 2021.

The mix of patient care revenue for the years ended August 31, 2024 and 2023 are as follows:

	<b>2024</b>		<b>2023</b>	
	<b>Health System</b>	<b>NYUGSoM</b>	<b>Health System</b>	<b>NYUGSoM</b>
Medicare	17 %	16 %	17 %	17 %
Medicaid	2	1	2	1
Medicare and Medicaid managed care	23	16	21	14
Blue Cross	26	20	26	20
Managed care and other	32	47	34	48
	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>

The mix of patient accounts receivable, net from patients and third-party payors at August 31, 2024 and 2023 are as follows:

	<b>2024</b>		<b>2023</b>	
	<b>Health System</b>	<b>NYUGSoM</b>	<b>Health System</b>	<b>NYUGSoM</b>
Medicare	9 %	11 %	9 %	11 %
Medicaid	1	1	2	1
Medicare and Medicaid managed care	25	16	23	13
Blue Cross	27	19	27	22
Managed care and other	38	53	39	53
	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>	<u>100 %</u>



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

NYU Langone Health is committed to ensuring that its care is not limited to those who have insurance coverage or the means to pay for care. NYU Langone Health recognizes that there are times when patients in need of care will have difficulty paying for the services provided. Accordingly, NYU Langone Health has implemented a discount policy and financial aid program that is consistent with the mission, values, and capacity of NYU Langone Health, while considering an individual's ability to contribute to their care.

As a matter of policy, NYU Langone Health provides significant amounts of partially or totally uncompensated patient care under its charity care policy or through its financial aid program. NYU Langone Health's charity care policy, in accordance with the New York State Department of Health guidelines, ensures the provision of quality health care to the community served while carefully considering the ability of the patient to pay. The policy has sliding fee schedules for inpatient, ambulatory and emergency services provided to the uninsured and under-insured patients that qualify. Patients are eligible for the charity care fee schedule if they meet certain income tests. Since payment of the difference between NYU Langone Health's standard charges and the charity care fee schedules is not sought, these forgone charges for charity care are not reported as revenue. Federal and state law requires that hospitals provide emergency services regardless of a patient's ability to pay. Under NYU Langone Health's charity care policy, the discount offered to uninsured patients is reflected as a reduction to net patient service revenue at the time the uninsured billings are recorded.

Uninsured patients seen in the emergency department, including patients subsequently admitted for inpatient services, often do not provide information necessary to allow NYU Langone Health to qualify such patients for charity care. Net patient service revenue related to uninsured patients who do not qualify for either Medicaid assistance or NYU Langone Health's financial aid program is recognized for the amount of consideration to which NYU Langone Health expects to be entitled in exchange for providing patient care, net of implicit price concessions based on historical collections. Implicit price concession rates for uninsured patients are refined on an annual basis.

Total charges associated with providing care to charity patients for the years ended August 31, 2024 and 2023, are \$488,454 and \$407,466, respectively. NYU Langone Health determines the cost of providing these services based on a ratio of cost to charges, as summarized in the table below.

New York State regulations provide for the distribution of funds from an indigent care pool, which is intended to partially offset the cost of uncompensated care and services provided to uninsured patients. The funds are distributed to NYU Langone Health based on an uninsured methodology. NYU Langone Health paid \$84,752 and \$77,740 into the indigent care pool for the years ended August 31, 2024 and 2023, respectively. Subsidy payments recognized as revenue to offset the cost of charity care provided are included in the table below.

In addition, a majority of NYU Langone Health's discharged patients during the years ended August 31, 2024 and 2023 were insured through government payors. NYU Langone Health incurs material costs in treating those patients, and does so at a loss given the shortfall in both Medicare and Medicaid reimbursement.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

The following table summarizes the estimated cost of the services provided, net reimbursement, and cost in excess of reimbursement for the years ended August 31, 2024 and 2023:

	2024	2023
<b>Costs of services provided</b>		
Charity Care	\$ 169,100	\$ 144,858
Governmental Payors	<u>6,567,975</u>	<u>5,720,451</u>
	<u>\$ 6,737,075</u>	<u>\$ 5,865,309</u>
<b>Net reimbursement</b>		
Charity Care	\$ 61,262	\$ 56,964
Governmental Payors	<u>4,444,795</u>	<u>3,910,722</u>
	<u>\$ 4,506,057</u>	<u>\$ 3,967,686</u>
<b>Costs of services in excess of reimbursement</b>		
Charity Care	\$ 107,838	\$ 87,894
Governmental Payors	<u>2,123,180</u>	<u>1,809,729</u>
	<u>\$ 2,231,018</u>	<u>\$ 1,897,623</u>

## 5. Investments

### Asset Classes

NYU invests across a broad range of asset classes, including public equity, fixed income, hedge funds, credit, real assets, private equity, real estate, and cash and other. NYU may invest directly in the securities of these asset classes, or indirectly through interests in funds and limited partnerships. Securities held directly by NYU are valued at their observable market prices. The value of holdings in funds and limited partnerships are in accordance with the valuations provided by their investment managers. Funds and limited partnerships may make investments in securities that are publicly traded, which are generally valued based on observable market prices. Managers of investment funds and limited partnerships value those investments based upon the best information available for a given circumstance and may incorporate assumptions that are the investment manager's best estimates after consideration of a variety of internal and external factors.

Investments held by NYU's investment pool are categorized as follows:

### Public Equity

Public equity consists of publicly-traded equity, mutual funds, and other commingled funds (which may include passive index exposure).

### Fixed Income

Fixed income includes investments in securities such as U.S. government securities, non-U.S. sovereign bonds, and corporate and asset-backed securities.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

**Cash and Other**

Cash and other predominantly includes cash and cash equivalents.

**U.S. Treasury Bills**

U.S. treasury bills include investments of U.S. treasury bills with an original maturity greater than three months at the time of purchase.

The fair value of the following asset classes is measured at NAV as a practical expedient:

**Real Assets**

Real assets include public and private investments in real asset funds.

**Hedge Funds**

Hedge funds include investments with managers who invest across different strategies such as long and short equity, multi-strategy, event driven and relative value funds. These managers typically employ some leverage.

**Credit**

Credit includes public and private investments in strategies including distressed debt and special situations.

**Private Equity**

Private equity investments include limited partnership investments in funds pursuing strategies in corporate buyouts, growth equity, and venture capital.

**Real Estate**

Real estate includes public and private investments in real estate funds.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

The following tables summarize the fair value of investments at August 31, 2024 and 2023:

	2024			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
<b>Long-term investments-investment pool</b>				
Public equity	\$ 1,562,157	\$ -	\$ -	\$ 1,562,157
Fixed income	-	503,938	-	503,938
Cash and other	142,197	-	-	142,197
	<u>1,704,354</u>	<u>503,938</u>	<u>-</u>	<u>2,208,292</u>
Alternative investments measured at NAV as a practical expedient				4,535,048
Subtotal investment pool				<u>6,743,340</u>
<b>Other long-term investments</b>				
Public equity	1,076,521	3,794	-	1,080,315
Fixed Income	10,091	-	-	10,091
Cash and other	2,498	-	5,720	8,218
Subtotal other long-term investments	<u>1,089,110</u>	<u>3,794</u>	<u>5,720</u>	<u>1,098,624</u>
Total long-term investments	<u>\$ 2,793,464</u>	<u>\$ 507,732</u>	<u>\$ 5,720</u>	<u>\$ 7,841,964</u>
<b>Short-term investments</b>				
Fixed income and other	\$ 221,041	\$ -	\$ -	\$ 221,041
U.S. Treasury bills	604,418	-	-	604,418
Total short-term investments	<u>\$ 825,459</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 825,459</u>

  

	2023			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
<b>Long-term investments-investment pool</b>				
Public equity	\$ 1,462,316	\$ -	\$ -	\$ 1,462,316
Fixed income	-	425,436	-	425,436
Cash and other	142,250	-	-	142,250
	<u>1,604,566</u>	<u>425,436</u>	<u>-</u>	<u>2,030,002</u>
Alternative investments measured at NAV as a practical expedient				3,868,965
Subtotal investment pool				<u>5,898,967</u>
<b>Other long-term investments</b>				
Public equity	893,347	3,702	-	897,049
Fixed income	9,217	-	-	9,217
Cash and other	1,952	-	4,920	6,872
Subtotal other long-term investments	<u>904,516</u>	<u>3,702</u>	<u>4,920</u>	<u>913,138</u>
Total long-term investments	<u>\$ 2,509,082</u>	<u>\$ 429,138</u>	<u>\$ 4,920</u>	<u>\$ 6,812,105</u>
<b>Short-term investments</b>				
Cash and other	\$ 457,077	\$ -	\$ -	\$ 457,077
U.S. Treasury bills	1,916,617	-	-	1,916,617
Total short-term investments	<u>\$ 2,373,694</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 2,373,694</u>

Level 3 activity was not significant for either of the years ended August 31, 2024 or 2023.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

The following tables represent NYU's investments measured at NAV as a practical expedient by asset class and the respective liquidity terms as of August 31, 2024 and 2023:

2024				
Asset Category	Redemption Frequency (if currently eligible)	Redemption Notice Period	Fair Value	
<b>Redeemable Alternative Investments</b>				
Public equity	Daily, Weekly, Monthly, Quarterly, Annual	1 to 90 days	\$	1,811,700
Hedge funds	Monthly, Quarterly, Semi-Annual, Annual	45 to 100 days		928,090
				<u>2,739,790</u>
<b>Nonredeemable Alternative Investments</b>	<b>Remaining Life</b>	<b>Time To Draw Commitment</b>	<b>Unfunded Commitments</b>	<b>Fair Value</b>
Private equity	Up to 12 years	7–14 days	\$ 780,532	\$ 1,080,806
Credit	Up to 5 years	7–14 days	96,466	255,553
Real assets	Up to 1 year	7–14 days	2,214	36,194
Real estate	Up to 12 years	7–14 days	276,798	422,705
			<u>\$ 1,156,010</u>	<u>1,795,258</u>
				<u>\$ 4,535,048</u>
2023				
Asset Category	Redemption Frequency (if currently eligible)	Redemption Notice Period	Fair Value	
<b>Redeemable Alternative Investments</b>				
Public equity	Daily, Weekly, Monthly, Quarterly, Annual	1 to 365 days	\$	1,477,590
Hedge funds	Monthly, Quarterly, Semi-Annual, Annual, Bi-Annual	15 to 365 days		890,061
				<u>2,367,651</u>
<b>Nonredeemable Alternative Investments</b>	<b>Remaining Life</b>	<b>Time To Draw Commitment</b>	<b>Unfunded Commitments</b>	<b>Fair Value</b>
Private equity	Up to 13 years	7–14 days	\$ 919,765	\$ 911,695
Credit	Up to 6 years	7–14 days	108,706	235,150
Real assets	Up to 2 years	7–14 days	2,450	38,376
Real estate	Up to 12 years	7–14 days	313,957	316,093
			<u>\$ 1,344,878</u>	<u>1,501,314</u>
				<u>\$ 3,868,965</u>

NYU maintains an investment pool for its long-term investments which include its endowment and similar funds. The pool is managed to achieve the maximum long-term return given prudent risk parameters. NYU relies on a total return strategy, the objective of which is to achieve a long-term rate of return consisting of a combination of current income and capital appreciation, recognizing that changes in market conditions and interest rates will result in varying strategies in an attempt to optimize results. Investment return (realized and unrealized net gains or losses, interest and dividends) and the appropriation for the approved endowment distribution for board-designated endowment funds are reported as nonoperating activities in the consolidated statements of activities. Investment return and the appropriation for the approved endowment distribution for

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

donor-restricted endowment funds are reported as changes in net assets with donor restrictions in the consolidated statements of activities.

NYU's Board of Trustees has authorized an endowment spending policy designed to allow asset growth while providing a predictable flow of return to support activities. Distributions from the endowment to support activities (approximately 4.5% in 2024 and 2023) are based on a fixed percentage of the 12-quarter average market value. To preserve the endowment's purchasing power, the endowment spending policy considers several factors including the purpose of the endowment funds, general economic conditions, the effect of inflation or deflation, expected return, availability of alternative sources of funding, and the investment policy.

**6. Accounts and Loans Receivable, Net**

Accounts and loans receivable, net of allowances for uncollectable amounts, consist of the following at August 31, 2024 and 2023:

	<b>2024</b>	<b>2023</b>
Students and other	\$ 258,653	\$ 272,763
Grants and contracts	183,809	220,925
Student loans	48,865	59,617
FEMA award receivable	145,984	91,570
Housing loans and other loans to employees	58,755	58,996
Insurance premiums and recoveries (Note 13)	77,604	89,094
	<u>773,670</u>	<u>792,965</u>
Allowance for uncollectible amounts	<u>(58,874)</u>	<u>(59,885)</u>
Accounts and loans receivable, net	<u>\$ 714,796</u>	<u>\$ 733,080</u>

Federal advances to the University under Perkins and other Federal loan programs totaled \$17,998 and \$21,305 at August 31, 2024 and 2023, respectively. NYU records a liability on its consolidated balance sheets for these advances within funds held for others.

A reasonable estimate of the fair value of loans receivable from students under government loan programs could not be made because the notes cannot be sold and can only be assigned to the U.S. government or its designees. The fair value of loans receivable from students under NYU's loan programs approximates carrying value.

Housing loans and other loans to employees are secured by an interest in the underlying property or continued employment.

NYU Langone Health has a balance due from the Federal Emergency Management Agency (FEMA) of \$128,750 and \$74,336 at August 31, 2024 and 2023, respectively, for reimbursement of eligible operating expenses and capital expenditures relating to COVID, as well as a balance due of \$17,234 at August 31, 2024 and 2023 relating to hazard mitigation projects as a result of Superstorm Sandy.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

(in thousands of dollars)

Management regularly assesses the adequacy of the allowance for credit losses by performing ongoing evaluation of the accounts and loans receivable portfolios.

**7. Contributions Receivable**

Contributions receivable consist of the following at August 31, 2024 and 2023:

	<b>2024</b>	<b>2023</b>
<b>Amounts expected to be collected in</b>		
Less than one year	\$ 241,646	\$ 265,474
One to five years	383,104	376,646
More than five years	<u>143,134</u>	<u>197,916</u>
	767,884	840,036
Discount	(50,231)	(46,130)
Allowance for uncollectible amounts	<u>(62,177)</u>	<u>(99,257)</u>
Contributions receivable, net	<u>\$ 655,476</u>	<u>\$ 694,649</u>

Contributions receivable activity for the years ended August 31, 2024 and 2023 is as follows:

	<b>2024</b>	<b>2023</b>
Contributions receivable, gross, beginning of year	\$ 840,036	\$ 743,226
New pledges received	223,430	290,320
Adjustments and write-offs	(91,774)	(14,006)
Pledge payments received	<u>(203,808)</u>	<u>(179,504)</u>
Contributions receivable, gross, end of year	767,884	840,036
Discount and allowance for uncollectible amounts	<u>(112,408)</u>	<u>(145,387)</u>
Contributions receivable, net, end of year	<u>\$ 655,476</u>	<u>\$ 694,649</u>

Conditional promises to give are not reported in the consolidated balance sheets and consist of the following as of August 31, 2024 and 2023:

	<b>2024</b>	<b>2023</b>
Bequests	\$ 1,213,453	\$ 1,158,403
Intentions to give	135,526	106,674
Conditional promises to give	<u>459,158</u>	<u>316,213</u>
	<u>\$ 1,808,137</u>	<u>\$ 1,581,290</u>

Expenses related to fundraising activities are \$63,865 and \$60,591 for the years ended August 31, 2024 and 2023, respectively.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

**8. Other Assets**

Other assets consist of the following at August 31, 2024 and 2023:

	2024	2023
Deferred compensation plan assets held for others	\$ 672,622	\$ 530,882
Prepaid expenses and deferred charges	222,184	221,029
Supplies inventory	217,567	210,329
Intangible assets and goodwill	21,736	51,105
Third-party payor receivables	82,346	75,755
Split-interest agreements	41,844	38,078
Net benefit asset (Note 14)	32,017	17,882
Other	97,694	94,690
	<u>\$ 1,388,010</u>	<u>\$ 1,239,750</u>
Other assets		

Deferred compensation plan assets held for others represent employee contributions and investment return for NYU's 457(b) plans. A corresponding obligation is recorded within funds held for others on the consolidated balance sheets.

NYU invests in various retirement plan assets as part of the deferred compensation plans. In addition to the asset classes described in Note 5, investments held by the deferred compensation plans also include:

**Variable Annuity**

Variable annuity contracts invest in a variety of public equity securities to generate varying rates of return based on the underlying public equities.

**Fixed Income Annuity**

Fixed income annuities are used to purchase a guaranteed amount of future retirement benefits.

The following tables summarize the fair value of other assets at August 31, 2024 and 2023:

	2024			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
<b>Other financial instruments</b>				
Split-interest agreements	\$ -	\$ -	\$ 41,844	\$ 41,844
<b>Deferred compensation plan assets held for others</b>				
Variable annuity contracts	\$ 225,914	\$ 59,154	\$ -	\$ 285,068
Fixed income annuities	25,135	6,073	58,188	89,396
Public equity	293,087	5,071	-	298,158
Total deferred compensation plan assets held for others	<u>\$ 544,136</u>	<u>\$ 70,298</u>	<u>\$ 58,188</u>	<u>\$ 672,622</u>



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

	2023			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
<b>Other financial instruments</b>				
Split-interest agreements	\$ -	\$ -	\$ 38,078	\$ 38,078
<b>Deferred compensation plan assets held for others</b>				
Variable annuity contracts	\$ 161,464	\$ 54,805	\$ -	\$ 216,269
Fixed income annuities	20,128	6,186	51,883	78,197
Public equity	232,706	3,710	-	236,416
Total deferred compensation plan assets held for others	\$ 414,298	\$ 64,701	\$ 51,883	\$ 530,882

Level 3 activity was not significant for either of the years ended August 31, 2024 or 2023.

**9. Deposits with Trustees**

Deposits with trustees include unexpended bond proceeds to fund various construction projects held by the trustee, the Dormitory Authority of the State of New York (DASNY), and debt service funds, and consist of the following at August 31, 2024 and 2023:

	2024	2023
Construction funds held by DASNY	\$ 88,902	\$ 322,870
Debt service reserve funds	21,470	20,396
Arbitrage rebate fund	2,885	-
Other	1,442	1,102
	<u>\$ 114,699</u>	<u>\$ 344,368</u>

The following tables summarize the fair value of deposits with trustees at August 31, 2024 and 2023 according to the asset categories defined in Note 5.

	2024			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 17,858	\$ 40,658	\$ -	\$ 58,516
Cash and other	56,183	-	-	56,183
Total deposits with trustees	\$ 74,041	\$ 40,658	\$ -	\$ 114,699

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

	2023			Total
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	
Fixed income	\$ 216,562	\$ 119,032	\$ -	\$ 335,594
Cash and other	8,774	-	-	8,774
Total deposits with trustees	<u>\$ 225,336</u>	<u>\$ 119,032</u>	<u>\$ -</u>	<u>\$ 344,368</u>

**10. Land, Buildings, and Equipment**

Land, buildings, and equipment consist of the following at August 31, 2024 and 2023:

	2024	2023
Land	\$ 403,038	\$ 403,038
Buildings and building improvements	17,667,218	16,704,403
Equipment	3,566,658	3,831,432
Finance leases	1,721,963	1,852,624
Construction in progress	<u>1,485,889</u>	<u>1,349,040</u>
	24,844,766	24,140,537
Less: Accumulated depreciation	<u>(9,649,397)</u>	<u>(9,620,758)</u>
Land, buildings, and equipment, net	<u>\$ 15,195,369</u>	<u>\$ 14,519,779</u>

Depreciation expense is \$1,104,251 and \$1,020,036 for the years ended August 31, 2024 and 2023, respectively.

During the year ended August 31, 2024, NYU Langone Health wrote off \$1,053,900 of fully depreciated assets.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

(in thousands of dollars)

**11. Leases**

The components of lease expense included in the consolidated statements of activities consist of the following for the years ended August 31, 2024 and 2023:

	2024	2023
<b>Lease cost</b>		
Finance lease cost		
Amortization of assets held under finance leases	\$ 87,700	\$ 88,994
Interest on finance lease obligations	75,885	74,726
Total finance lease cost	<u>163,585</u>	<u>163,720</u>
Operating lease cost	328,611	316,346
Short-term and variable lease costs	54,295	40,042
Total operating lease cost included in facilities costs	<u>382,906</u>	<u>356,388</u>
Total lease cost	<u>\$ 546,491</u>	<u>\$ 520,108</u>
<b>Other information</b>		
Cash paid for amounts included in the measurement of lease obligations		
Operating cash flows for operating leases	\$ 310,809	\$ 296,942
Operating cash flows for finance leases	75,885	74,726
Financing cash flows for finance leases	37,300	56,463
Right-of-use assets obtained		
In exchange for new operating lease obligations	\$ 307,722	\$ 205,015
In exchange for new finance lease obligations (Note 10)	80,883	233,624
Weighted-average remaining lease term		
Operating leases	18.1 years	18.3 years
Operating leases excluding ground lease through 2087	11.7 years	11.8 years
Finance leases	26.0 years	26.7 years
Weighted-average discount rate		
Operating leases	3.51 %	3.20 %
Finance leases	4.06 %	4.01 %

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

(in thousands of dollars)

Aggregate future minimum lease payments under operating leases as of August 31, 2024 are as follows:

2025	\$ 320,899
2026	286,852
2027	257,642
2028	206,638
2029	189,575
Thereafter	<u>2,005,546</u>
Total minimum lease payments	3,267,152
Less: Imputed interest	<u>(1,003,636)</u>
Total operating lease obligation	<u>\$ 2,263,516</u>

The difference between fixed operating lease payments and lease expense on a straight line basis is \$206,943 at August 31, 2024, and is recorded as a reduction to the operating ROU asset on the consolidated balance sheet.

## 12. Debt and Other Obligations

NYU has various bond issues outstanding, primarily issued through DASNY. The University and NYU Schools of Medicine are considered the legally obligated group for certain borrowings presented below as the "Obligated Group."

Debt and other obligations consist of the following at August 31, 2024 and 2023:

	2024				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
<b>Issuer</b>					
Dormitory Authority of the State of New York (DASNY)	\$ 3,457,997	\$ 760,886	\$ 4,218,883	\$ 745,575	\$ 4,964,458
New York University	222,827	47,906	270,733	-	270,733
NYU Langone Hospitals	-	-	-	2,040,566	2,040,566
Nassau County Local Economic Assistance Corporation	-	-	-	24,880	24,880
Brookhaven Local Development Corporation	-	-	-	80,227	80,227
Other obligations	<u>449,336</u>	<u>1,524,114</u>	<u>1,973,450</u>	<u>305,371</u>	<u>2,278,821</u>
Debt and other obligations	<u>\$ 4,130,160</u>	<u>\$ 2,332,906</u>	<u>\$ 6,463,066</u>	<u>\$ 3,196,619</u>	<u>\$ 9,659,685</u>
	2023				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
<b>Issuer</b>					
Dormitory Authority of the State of New York (DASNY)	\$ 3,581,126	\$ 785,226	\$ 4,366,352	\$ 770,279	\$ 5,136,631
New York University	234,395	52,616	287,011	-	287,011
NYU Langone Hospitals	-	-	-	2,040,206	2,040,206
Nassau County Local Economic Assistance Corporation	-	-	-	26,576	26,576
Brookhaven Local Development Corporation	-	-	-	82,199	82,199
Other obligations	<u>165,640</u>	<u>1,590,156</u>	<u>1,755,796</u>	<u>339,849</u>	<u>2,095,645</u>
Debt and other obligations	<u>\$ 3,981,161</u>	<u>\$ 2,427,998</u>	<u>\$ 6,409,159</u>	<u>\$ 3,259,109</u>	<u>\$ 9,668,268</u>

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

(in thousands of dollars)

The principal amounts outstanding for debt and other obligations consist of the following at August 31, 2024 and 2023:

	2024				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
<b>DASNY</b>					
Series 1998A bonds, with an interest rate of 5.75% payable in annual sinking fund installments to maturity in 2027 (including premium of \$470)	\$ 49,660	\$ -	\$ 49,660	\$ -	\$ 49,660
2001 Series 1 bonds, with an interest rate of 5.50%, maturing serially in July 2025, payable thereafter in annual sinking fund installments to maturities in July 2031 and July 2040 (including premiums of \$1,256 and \$1,687)	48,757	40,551	89,308	-	89,308
Series 2012C taxable bonds, with interest rates ranging from 3.42% to 3.62%, maturing serially through July 2027	6,940	-	6,940	-	6,940
Series 2013B taxable bonds, with interest rates ranging from 4.18% to 5.25%, maturing serially through July 2028, payable thereafter in annual sinking fund installments to maturities in July 2033 and July 2043	18,595	-	18,595	-	18,595
Series 2014 bonds, with interest rate ranging from 2.00% to 5.00%, maturing serially through July 2032 and July 2036 (including premium of \$5,293)	-	-	-	58,453	58,453
Series 2014 S2 bonds, with interest rate ranging from 3.75% to 4.95%, maturing serially through July 2034 and July 2035 (including premium of \$9,859)	-	-	-	70,414	70,414
Series 2014A taxable bonds, with an interest rate of 2.59% maturing in July 2034, payable in annual sinking fund installments through July 2034	37,010	-	37,010	-	37,010
Series 2015 bonds, with interest rates ranging from 2.80% to 5.00%, maturing serially through July 2035, payable in annual sinking fund installments from July 2036 to July 2048 (including premium of \$45,475)	563,825	-	563,825	-	563,825
Series 2016A bonds, with interest rates ranging from 3.00% to 5.00%, maturing serially through July 2036 payable thereafter in annual sinking fund installments until July 2043 (including premiums of \$44,490 and \$17,310)	420,640	128,130	548,770	-	548,770
Series 2016B taxable bonds, with an interest rate of 3.88%, payable in annual sinking fund installments until July 2046	141,090	29,970	171,060	-	171,060
Series 2016A bonds, with interest rates ranging from 3.53% to 4.77%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2043 (including premium of \$15,579)	-	-	-	107,339	107,339
Series 2017A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2047 (including premium of \$22,139 and \$16,869)	256,660	153,417	410,077	-	410,077
Series 2017B taxable bonds, with interest rates ranging from 2.88% to 4.15%, maturing serially to maturity in July 2032	156,579	50,406	206,985	-	206,985
Series 2018A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$23,565 and \$7,796)	266,605	71,846	338,451	-	338,451
Series 2018B taxable bonds, with interest rates ranging from 3.39% to 4.85%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$5,487 and \$2,330)	145,627	96,855	242,482	-	242,482
Series 2019A bonds, with interest rates ranging from 4.00% to 5.00%, maturing serially through July 2049 payable thereafter in annual sinking fund installments (including premiums of \$61,678 and \$10,515)	552,469	86,320	638,789	-	638,789
Series 2019B-1 taxable bonds, with an interest rate of 4.29%, payable in annual sinking fund installments until July 2044	136,505	14,435	150,940	-	150,940
Series 2019B-2 taxable bonds, with an interest rate of 4.01% payable in annual sinking fund installments maturing on July 2049	77,925	5,245	83,170	-	83,170

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

(in thousands of dollars)

	2024				
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
Series 2020A bonds, with interest rates ranging from 3.00% to 4.00% maturing serially through July 2053 (including net premiums of \$46,578)	-	-	-	512,883	512,883
Series 2020B taxable bonds, with interest rates ranging from 1.54% to 2.77%, maturing serially through July 2030 and payable thereafter in annual sinking fund installments to maturity in 2043	354,050	33,050	387,100	-	387,100
Series 2021A bonds, with interest rates ranging from 2.25% to 5.00%, maturing serially through July 2041 and payable thereafter in annual sinking fund installments to maturity in 2051 (including premiums of \$35,563 and \$9,263)	208,623	48,898	257,521	-	257,521
Series 2021B taxable bonds, with interest rates ranging from 0.93% to 2.02%, maturing serially through July 2031	26,080	3,025	29,105	-	29,105
Deferred financing costs	(9,643)	(1,262)	(10,905)	(3,514)	(14,419)
Subtotal of DASNY bonds	3,457,997	760,886	4,218,883	745,575	4,964,458
<b>NYU</b>					
Series 2009 taxable bonds, with an interest rate of 5.24%, payable in annual sinking fund installments through July 2032	9,241	48,209	57,450	-	57,450
Series 2010 taxable bonds, with an interest rate of 4.96%, payable in annual sinking fund installments through July 2032	14,110	-	14,110	-	14,110
Series 2015 taxable bonds, with interest rates ranging from 2.97% to 4.14%, maturing serially through July 2028, payable in annual sinking fund installments from July 2029 to July 2048	200,085	-	200,085	-	200,085
Deferred financing costs	(609)	(303)	(912)	-	(912)
Subtotal of NYU bonds	222,827	47,906	270,733	-	270,733
<b>NYU Langone Hospitals</b>					
Series 2012 taxable bonds, with an interest rate of 4.40%, maturing in July 2042 (including discount of \$620)	-	-	-	249,380	249,380
Series 2013 taxable bonds, with an interest rate of 5.75%, maturing in July 2043 (including discount of \$907)	-	-	-	349,093	349,093
Series 2014 taxable bonds, with an interest rate of 4.78%, maturing in July 2044 (including discount of \$837)	-	-	-	299,163	299,163
Series 2017A taxable bonds, with an interest rate ranging from 4.17% to 4.37%, maturing in August 2047	-	-	-	600,000	600,000
Series 2020B taxable bonds, with a fixed interest rate of 3.38% to maturity in July 2055 (including a discount of \$2,364)	-	-	-	548,661	548,661
Deferred financing costs	-	-	-	(5,731)	(5,731)
Subtotal of NYU Langone Hospitals bonds	-	-	-	2,040,566	2,040,566
<b>Nassau County Local Economic Assistance Corporation</b>					
Series 2014 taxable bonds, with interest rates ranging from 2.99% to 4.32%, maturing in July 2036	-	-	-	24,880	24,880
Subtotal of Nassau County Local Economic Assistance Corporation bonds	-	-	-	24,880	24,880
<b>Brookhaven Local Development Corporation</b>					
Series 2020A taxable bond series, with varying interest rates of 4.2% to 5.0%, maturing in October 2050 (including premium of \$6,857)	-	-	-	65,992	65,992
Series 2020B taxable bond series, with varying interest rates of 5.5% to 6.0%, maturing in October 2030 (including premium of \$1,110)	-	-	-	14,235	14,235
Subtotal of Brookhaven Local Development Corporation	-	-	-	80,227	80,227
<b>Other obligations</b>					
Mortgage loans	-	141,301	141,301	301	141,602
Commercial paper	233,200	-	233,200	-	233,200
Commercial loans	-	-	-	918	918
Lines of credit	28,200	24,490	52,690	-	52,690
Finance leases (Note 10)	187,936	1,358,323	1,546,259	304,152	1,850,411
Subtotal of other obligations	449,336	1,524,114	1,973,450	305,371	2,278,821
Total amounts outstanding	\$ 4,130,160	\$ 2,332,906	\$ 6,463,066	\$ 3,196,619	\$ 9,659,685

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

(in thousands of dollars)

					2023		
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU		
<b>DASNY</b>							
Series 1998A bonds, with interest rates ranging from 5.75% to 6.00%, maturing serially through July 2020, payable thereafter in annual sinking fund installments to maturity in 2027 (including premium of \$770)	\$ 64,605	\$ -	\$ 64,605	\$ -	\$ 64,605		
2001 Series 1 bonds, with an interest rate of 5.50%, maturing serially from July 2011, through July 2025, payable thereafter in annual sinking fund installments to maturities in July 2031 and July 2040 (including premiums of \$1,392 and \$1,794)	50,718	42,152	92,870	-	92,870		
Series 2012C taxable bonds, with interest rates ranging from 3.27% to 3.62%, maturing serially through July 2027	9,225	-	9,225	-	9,225		
Series 2013B taxable bonds, with interest rates ranging from 3.98% to 5.25%, maturing serially through July 2028, payable thereafter in annual sinking fund installments to maturities in July 2033 and July 2043	20,065	-	20,065	-	20,065		
Series 2014 bonds, with interest rate ranging from 2.00% to 5.00%, maturing serially through July 2032 and July 2036 (including premium of \$5,737)	-	-	-	62,467	62,467		
Series 2014 S2 bonds, with interest rate ranging from 3.75% to 4.95%, maturing serially through July 2034 and July 2035 (including premium of \$10,755)	-	-	-	75,820	75,820		
Series 2014A taxable bonds, with an interest rate of 2.59% maturing in July 2034, payable in annual sinking fund installments through July 2034	40,205	-	40,205	-	40,205		
Series 2015 bonds, with interest rates ranging from 2.00% to 5.50%, maturing serially through July 2035, payable in annual sinking fund installments from July 2036 to July 2048 (including premium of \$49,266)	585,871	-	585,871	-	585,871		
Series 2016A bonds, with interest rates ranging from 2.00% to 5.00%, maturing serially through July 2036 payable thereafter in annual sinking fund installments until July 2043 (including premiums of \$48,996 and \$18,103)	439,741	132,893	572,634	-	572,634		
Series 2016B taxable bonds, with interest rates ranging from 1.20% to 5.00%, maturing serially through July 2022 payable thereafter in annual sinking fund installments until July 2046	141,090	29,970	171,060	-	171,060		
Series 2016A bonds, with interest rates ranging from 3.53% to 4.77%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2043 (including premium of \$16,568)	-	-	-	121,053	121,053		
Series 2017A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially to maturity in July 2040 and payable thereafter in annual sinking fund installments until July 2047 (including premium of \$25,459 and \$17,608)	273,243	157,629	430,872	-	430,872		
Series 2017B taxable bonds, with interest rates ranging from 2.73% to 4.15%, maturing serially to maturity in July 2032	160,229	50,406	210,635	-	210,635		
Series 2018A bonds, with interest rates ranging from 3.25% to 5.00%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$25,942 and \$8,124)	277,407	74,235	351,642	-	351,642		
Series 2018B taxable bonds, with interest rates ranging from 3.24% to 4.85%, maturing serially through July 2048 payable thereafter in annual sinking fund installments (including premiums of \$5,758 and \$2,428)	145,899	98,638	244,537	-	244,537		
Series 2019A bonds, with interest rates ranging from 4.00% to 5.00%, maturing serially through July 2049 payable thereafter in annual sinking fund installments (including premiums of \$66,418 and \$10,939)	567,114	86,744	653,858	-	653,858		
Series 2019B-1 taxable bonds, with interest rates ranging from 2.99% to 4.29%, payable in annual sinking fund installments through July 2044	136,505	20,995	157,500	-	157,500		
Series 2019B-2 taxable bonds, with an interest rate of 4.01% payable in annual sinking fund installments maturing on July 2049	77,925	5,245	83,170	-	83,170		

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

(in thousands of dollars)

			2023		
	University	NYU Schools of Medicine	Total Obligated Group	Health System	Consolidated NYU
Series 2020A bonds, with interest rates ranging from 3.00% to 4.00% maturing serially through July 2053 (including net premiums of \$50,320)	-	-	-	516,625	516,625
Series 2020B taxable bonds, with interest rates ranging from 1.44% to 2.77%, maturing serially through July 2030 and payable thereafter in annual sinking fund installments to maturity in 2043	361,145	34,665	395,810	-	395,810
Series 2021A bonds, with interest rates ranging from 0.66% to 2.23%, maturing serially through July 2041 and payable thereafter in annual sinking fund installments to maturity in 2051 (including premiums of \$37,621 and \$9,607)	210,681	49,242	259,923	-	259,923
Series 2021B taxable bonds, with interest rates ranging from 0.67% to 2.02%, maturing serially through July 2031	29,965	3,760	33,725	-	33,725
Deferred financing costs	(10,507)	(1,348)	(11,855)	(5,686)	(17,541)
Subtotal of DASNY bonds	3,581,126	785,226	4,366,352	770,279	5,136,631
<b>NYU</b>					
Series 2009 taxable bonds, with an interest rate of 5.24%, payable in annual sinking fund installments through July 2032	10,153	52,967	63,120	-	63,120
Series 2010 taxable bonds, with an interest rate of 4.96%, payable in annual sinking fund installments through July 2032	15,505	-	15,505	-	15,505
Series 2015 taxable bonds, with interest rates ranging from 2.87% to 4.14%, maturing serially through July 2028, payable in annual sinking fund installments from July 2029 to July 2048	209,415	-	209,415	-	209,415
Deferred financing costs	(678)	(351)	(1,029)	-	(1,029)
Subtotal of NYU bonds	234,395	52,616	287,011	-	287,011
<b>NYU Langone Hospitals</b>					
Series 2012 taxable bonds, with an interest rate of 4.40%, maturing in July 2042 (including discount of \$655)	-	-	-	249,345	249,345
Series 2013 taxable bonds, with an interest rate of 5.75%, maturing in July 2043 (including discount of \$955)	-	-	-	349,045	349,045
Series 2014 taxable bonds, with an interest rate of 4.78%, maturing in July 2044 (including discount of \$879)	-	-	-	299,121	299,121
Series 2017A taxable bonds, with an interest rate ranging from 4.17% to 4.37%, maturing in August 2047	-	-	-	600,000	600,000
Series 2020B taxable bonds, with a fixed interest rate of 3.38% to maturity in July 2055 (including a discount of \$2,441)	-	-	-	548,584	548,584
Deferred financing costs	-	-	-	(5,889)	(5,889)
Subtotal of NYU Langone Hospitals bonds	-	-	-	2,040,206	2,040,206
<b>Nassau County Local Economic Assistance Corporation</b>					
Series 2014 taxable bonds, with interest rates ranging from 2.99% to 4.32%, maturing in July 2036	-	-	-	26,576	26,576
Subtotal of Nassau County Local Economic Assistance Corporation bonds	-	-	-	26,576	26,576
<b>Brookhaven Local Development Corporation</b>					
Series 2020A taxable bond series, with varying interest rates of 4.2% to 5.0%, maturing in October 2050 (including premium of \$7,119)	-	-	-	66,254	66,254
Series 2020B taxable bond series, with varying interest rates of 5.5% to 6.0%, maturing in October 2030 (including premium of \$1,290)	-	-	-	15,945	15,945
Subtotal of Brookhaven Local Development Corporation	-	-	-	82,199	82,199
<b>Other obligations</b>					
Mortgage loans	-	142,137	142,137	2,179	144,316
Commercial loans	-	-	-	13,359	13,359
Lines of credit	-	35,330	35,330	-	35,330
Finance leases (Note 10)	165,640	1,412,689	1,578,329	324,311	1,902,640
Subtotal of other obligations	165,640	1,590,156	1,755,796	339,849	2,095,645
Total amounts outstanding	\$ 3,981,161	\$ 2,427,998	\$ 6,409,159	\$ 3,259,109	\$ 9,668,268



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

(in thousands of dollars)

Interest expense on debt and other obligations totaled \$374,220 and \$372,396 for the years ended August 31, 2024 and 2023, respectively. This excludes \$19,946 and \$20,401 of interest capitalized (net of income earned on deposits with bond trustees) for the years ended August 31, 2024 and 2023, respectively, which is included in land, buildings, and equipment, net.

NYU enters into various debt and other loan agreements that are secured by specific revenue streams, collateral and other real property or improvements, in addition to issuing debt supported by a general obligation of the Obligated Group, any of which may constrain the use of certain assets. Other agreements include covenants requiring that NYU Langone Hospitals maintains certain financial ratios. At August 31, 2024 and 2023, the Obligated Group and NYU Langone Health are compliant with all financial covenants.

**Obligations with Financial Institutions**

At August 31, 2024 and 2023, the Obligated Group has three contractually committed bank credit agreements which total \$800,000. As of August 31, 2024, these agreements expire from May 2025 to August 2026. Interest is accrued at rates based on the Secured Overnight Financing Rate. The amounts outstanding under these agreements are \$52,690 and \$35,330 as of August 31, 2024 and 2023, respectively.

At August 31, 2024, NYU Langone Hospitals has five unsecured lines of credit totaling \$718,800. At August 31, 2023, NYU Langone Hospitals had four unsecured lines of credit totaling \$679,800. As of August 31, 2024 these agreements expire from April 2025 to August 2026. Interest is accrued at rates based on the Secured Overnight Financing Rate. There were no amounts outstanding as of August 31, 2024 and 2023, respectively.

The Obligated Group established a commercial paper program in May 2024 with a maximum authorized amount of \$250,000. The amount outstanding was \$233,200 as of August 31, 2024.

**Future Principal Payments**

The aggregate required principal payments on all debt and other obligations, including capital leases, for each of the next five fiscal years, and thereafter to maturity, are as follows:

<b>Year Ending August 31,</b>	<b>Debt and Other Obligations</b>	<b>Finance Leases</b>	<b>Total</b>
2025	\$ 472,297	\$ 105,903	\$ 578,200
2026	177,402	107,660	285,062
2027	284,932	107,733	392,665
2028	171,357	100,473	271,830
2029	177,616	103,729	281,345
Thereafter	6,160,291	2,669,228	8,829,519
	<u>7,443,895</u>	<u>3,194,726</u>	<u>10,638,621</u>
Unamortized premiums and discounts, net	386,441	-	386,441
Unamortized deferred financing costs	(21,062)	-	(21,062)
Less: Imputed interest	-	(1,344,315)	(1,344,315)
	<u>\$ 7,809,274</u>	<u>\$ 1,850,411</u>	<u>\$ 9,659,685</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

(in thousands of dollars)

**13. Professional Liabilities**

NYU Langone Hospitals' professional liabilities are reported on a discounted basis and comprise estimates for known reported losses and loss expenses plus a provision for losses incurred but not reported. Losses are actuarially determined and are based on the loss experience of the insured. In management's opinion, recorded reserves for both self-insured and commercially insured exposures are adequate to cover the ultimate net cost of losses incurred to date; however, the provision is based on estimates and may ultimately be settled for a significantly greater or lesser amount.

Professional liabilities consist of the following as of August 31, 2024 and 2023:

	<b>2024</b>	<b>2023</b>
CCC550 professional liabilities	\$ 917,622	\$ 840,264
Self-insured liabilities	37,400	45,200
LICH self-insured liabilities	29,460	30,147
Commercially insured liabilities	<u>48,119</u>	<u>51,426</u>
Professional liabilities	<u>\$ 1,032,601</u>	<u>\$ 967,037</u>

NYU Langone Hospitals is self-insured for professional and general liabilities on an occurrence basis through CCC550. CCC550 provides insurance coverage to certain voluntary attending physicians and other non-employed physicians serving NYUGSoM and NYU Langone Hospitals. The cost of this insurance coverage is the responsibility of such physicians.

Prior to July 1, 2017, NYU Langone Hospital-Long Island was self-insured for professional liabilities and designated funds in a revocable trust for satisfaction of claims and expenses. LICH is self-insured for professional liabilities.

Commercially insured liabilities relate to policies purchased by NYU Langone Hospital-Brooklyn and NYU Langone Hospital-Long Island (for certain of its physicians) covering periods prior to October 1, 2015 and July 1, 2017, respectively. NYU Langone Hospitals recorded a corresponding insurance recovery receivable for claims covered by these policies within accounts and loans receivable, net on the consolidated balance sheets (Note 6).

Assets held for professional liabilities consist of the following at August 31, 2024 and 2023:

	<b>2024</b>	<b>2023</b>
Assets held by CCC550	\$ 1,281,349	\$ 1,044,422
Self-insurance trust	<u>21,265</u>	<u>52,178</u>
Assets held for professional liabilities	<u>\$ 1,302,614</u>	<u>\$ 1,096,600</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

The following tables summarize the fair value of assets held for professional liabilities at August 31, 2024 and 2023 according to the asset categories defined in Note 5:

	2024			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Fixed income	\$ 101,284	\$ 924,716	\$ -	\$ 1,026,000
Equity	226,362	-	-	226,362
Cash and other	50,252	-	-	50,252
Total assets held for professional liabilities	<u>\$ 377,898</u>	<u>\$ 924,716</u>	<u>\$ -</u>	<u>\$ 1,302,614</u>

  

	2023			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Fixed income	\$ 109,292	\$ 788,926	\$ -	\$ 898,218
Equity	169,547	-	-	169,547
Cash and other	28,835	-	-	28,835
Total assets held for professional liabilities	<u>\$ 307,674</u>	<u>\$ 788,926</u>	<u>\$ -</u>	<u>\$ 1,096,600</u>

#### 14. Pension Plans and Other Postretirement Benefits

##### Pension Plans

Substantially all NYU employees are covered by retirement plans including various defined contribution plans, multi-employer defined benefit plans, and three NYU-sponsored benefit plans.

##### *Defined Contribution Plans*

Contributions to the defined contribution plans are based on rates required by union contracts or other contractual arrangements. Contributions of \$376,109 and \$331,747 in 2024 and 2023, respectively, are reported as expenses in the consolidated statements of activities. There is no obligation on the consolidated balance sheets for these plans.

##### *Multi-Employer Defined Benefit Plans*

Contributions to the multi-employer defined benefit plans are based on rates required by union contracts and other contractual arrangements. Contributions of \$309,860 and \$266,009 in 2024 and 2023, respectively, are reported as expenses in the consolidated statements of activities. There is no obligation on the consolidated balance sheets for these plans.

##### *Defined Benefit Plans*

Contributions to the three defined benefit plans are intended to provide benefits attributed to service to date, as well as for those expected to be earned in the future. Contributions are made in amounts sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974 as amended under the Pension Protection Act of 2006 (ERISA), plus such additional amounts as the sponsors may deem appropriate. Pension benefits under these defined benefit plans are based on participants' final average compensation levels and years of service and are accrued during the period the employees provide service to NYU. Contributions of \$44,436 and \$17,450 in 2024 and 2023, respectively, are reported as a reduction in the accrued benefit obligation on the consolidated balance sheets for these plans.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

**Postretirement Benefits**

NYU has three defined benefit health and welfare plans that provide certain health care and life insurance benefits for eligible retired employees. NYU employees may become eligible for these benefits if they reach the age and service requirements of the plan while working for NYU. The costs related to these plans are accrued during the period the employees provide service to NYU. Contributions of \$31,574 and \$28,750 in 2024 and 2023, respectively, are reported as a reduction in the accrued postretirement obligation on the consolidated balance sheets for these plans.

The following tables provide information with respect to the defined benefit and other postretirement benefit plans for the years ended August 31:

**Plans' Funded Status**

	<b>Defined Benefit Pension Plans</b>		<b>Postretirement Benefit Plans</b>	
	<b>2024</b>	<b>2023</b>	<b>2024</b>	<b>2023</b>
<b>Change in benefit obligation</b>				
Benefit obligation as of beginning of year	\$ 2,046,216	\$ 2,214,034	\$ 677,306	\$ 705,504
Service cost	30,038	38,507	13,689	14,992
Interest cost	109,650	103,033	34,249	32,313
Actuarial loss (gain)	144,683	(204,325)	46,800	(53,138)
Benefits paid	(104,720)	(102,984)	(31,905)	(32,221)
Participant contributions	-	-	7,989	8,725
Retiree drug subsidy receipts	-	-	608	1,131
Administrative expenses	(1,040)	(2,049)	-	-
Benefit obligation as of end of year	<u>2,224,827</u>	<u>2,046,216</u>	<u>748,736</u>	<u>677,306</u>
<b>Change in fair value of plan assets</b>				
Fair value of plan assets as of beginning of year	1,835,011	1,815,316	220,489	194,766
Actual return on plan assets	251,310	107,278	40,027	19,338
Employer contributions	44,436	17,450	31,574	28,750
Benefits paid	(104,720)	(102,984)	(31,905)	(32,221)
Participant contributions	-	-	7,989	8,725
Retiree drug subsidy receipts	-	-	608	1,131
Administrative expenses	(1,040)	(2,049)	-	-
Fair value of plan assets, end of year	<u>2,024,997</u>	<u>1,835,011</u>	<u>268,782</u>	<u>220,489</u>
Net benefit asset (Note 8)	<u>(32,017)</u>	<u>(17,882)</u>	<u>-</u>	<u>-</u>
Accrued benefit obligation	<u>\$ 231,847</u>	<u>\$ 229,087</u>	<u>\$ 479,954</u>	<u>\$ 456,817</u>
<b>Benefit obligation range of assumptions as of August 31</b>				
Discount rate	5.15%–5.30%	5.30%–5.61%	5.05%–5.19%	5.24%–5.57%
Rate of increase in compensation levels	3.50%–6.00%	2.91%–6.00%	N/A	N/A

The accumulated benefit obligation for the defined benefit pension plans is \$2,092,807 and \$1,941,263 at August 31, 2024 and 2023, respectively.

Actuarial gains and losses were the result of asset returns in excess of planned return as well as changes in discount rates and plan experience for the year ended August 31, 2024 and 2023.

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

(in thousands of dollars)

#### Net Periodic Benefit Cost

	Defined Benefit Pension Plans		Postretirement Benefit Plans	
	2024	2023	2024	2023
<b>Components of net periodic benefit cost</b>				
Operating expense				
Service cost in salary and fringe	\$ 30,038	\$ 38,507	\$ 13,689	\$ 14,992
Nonoperating expense				
Interest cost	109,650	103,033	34,249	32,313
Expected return on plan assets	(137,627)	(139,431)	(13,137)	(11,602)
Amortization of prior service credit	-	-	(4,045)	(4,113)
Amortization of actuarial (gain) loss	(1,663)	-	(2,016)	930
Total nonservice costs	(29,640)	(36,398)	15,051	17,528
Net periodic benefit cost	\$ 398	\$ 2,109	\$ 28,740	\$ 32,520
<b>Other changes recognized in net assets without donor restrictions</b>				
Actuarial net loss (gain) arising during period	\$ 31,001	\$ (172,171)	\$ 19,909	\$ (60,875)
Amortization of prior service credit	-	-	4,045	4,113
Amortization of actuarial gain (loss)	1,663	-	2,016	(930)
Total changes in pension and postretirement obligations	\$ 32,664	\$ (172,171)	\$ 25,970	\$ (57,692)
<b>Net periodic benefit cost range of assumptions</b>				
Discount rate	5.30%–5.65%	4.70%–5.00%	5.25%–5.58%	4.89%–5.25%
Rate of increase in compensation levels	2.91%–6.00%	2.91%–5.00%	N/A	N/A
Expected long-term rate of return on plan assets	6.00%–7.00%	6.00%–7.00%	6.00%–7.00%	6.00%–7.00%
Initial healthcare cost trend	N/A	N/A	7.50%–39.25%	6.50%–10.05%
Ultimate retiree health-care cost trend	N/A	N/A	4.50%	4.50%
Year ultimate trend rate is achieved	N/A	N/A	2031–2035	2030–2032

Amounts not yet reflected in net periodic benefit cost and included in net assets without donor restrictions for the defined benefit pension plans totaled \$152,482 and \$119,818 for the years ended August 31, 2024 and 2023, respectively. Amounts not yet reflected in net periodic benefit cost and included in net assets without donor restrictions for the postretirement benefit plans totaled (\$81,142) and (\$107,965) for the years ended August 31, 2024 and 2023, respectively.

#### Plan Assets

The following table presents the fair value of the defined benefit plan investments at August 31, 2024 and 2023 according to the asset categories defined in Note 5:

	2024		
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
			Total
Public equity	\$ 771,238	\$ 341,708	\$ -
Fixed income	573,371	271,619	-
Cash and other	67,061	-	-
	\$ 1,411,670	\$ 613,327	\$ -

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

	2023			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Public equity	\$ 734,669	\$ 304,102	\$ -	\$ 1,038,771
Fixed income	484,655	240,254	-	724,909
Cash and other	70,894	-	-	70,894
	<u>\$ 1,290,218</u>	<u>\$ 544,356</u>	<u>\$ -</u>	<u>1,834,574</u>
Alternative investments measured at NAV as a practical expedient				437
				<u>\$ 1,835,011</u>

The defined benefit pension assets seek to: (1) provide retirement benefits to its participants and beneficiaries; and (2) achieve full funding of the pension liability, while incurring an acceptable level of risk for the sponsor. The pension liability growth rate together with the objective to achieve and maintain a fully-funded level over a reasonable timeline implies a minimum absolute rate of return to be met through either: (1) annual budgeted contributions, (2) pension assets growth, (3) plan de-risking improvements, or (4) a combination thereof.

The strategy for achieving and maintaining a fully funded pension liability may vary with the prevailing funded level and other parameters related to the overall goal. The asset allocation process is designed to be dynamic and employ a liability-driven, glide path investment strategy, which reframes risk and performance relative to the pension liability. This approach is expected to enable pension assets to more reliably track the value of the pension liability, with less funded level volatility, than a static total-return investment. Broad target allocations at the current funded level are 55-75% return-seeking assets, such as equity and real estate (REIT) funds, and 25-45% liability-hedging assets, such as fixed income funds. The expected long-term rate of return assumption is determined by adding expected inflation to expected long-term real returns of various asset classes, weighing the asset class returns by the plans' investment in each class, and taking into account expected volatility and correlation between the returns of various asset classes. NYU management believes 6-7% is a reasonable estimate of long-term rates of return on plan assets for 2024 and will continue to evaluate the actuarial assumptions and adjust them as necessary.

The following table presents the fair value of the postretirement benefit plan investments at August 31, 2024 and 2023 according to the asset categories defined in Note 5:

	2024			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Public equity	\$ 185,934	\$ -	\$ -	\$ 185,934
Fixed income	78,126	3,554	-	81,680
Cash and other	1,168	-	-	1,168
	<u>\$ 265,228</u>	<u>\$ 3,554</u>	<u>\$ -</u>	<u>\$ 268,782</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

	2023			
	Active Markets (Level 1)	Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total
Public equity	\$ 149,162	\$ -	\$ -	\$ 149,162
Fixed income	64,207	7,120	-	71,327
	<u>\$ 213,369</u>	<u>\$ 7,120</u>	<u>\$ -</u>	<u>\$ 220,489</u>

The plans' investment objectives seek a long-term total rate of return to meet NYU's current and future plan obligations.

The postretirement benefit plan target asset allocation mix is 70% equity and 30% fixed income and cash, for which each asset class has a permitted range of +/- 10%.

The expected long-term rate of return assumption is determined by adding expected inflation to expected long-term real returns of various asset classes, taking into account expected volatility and correlation between the returns of various asset classes. NYU management believes that 6%-7% is a reasonable range of long-term rates of return on plan assets for 2024 and will continue to evaluate the actuarial assumptions and adjust them as necessary.

### Contributions

NYU determines the annual contributions to the plans based upon calculations prepared by the plans' actuaries. Total expected contributions for the defined benefit pension plans and other postretirement benefit plans in fiscal year 2025 are \$104,300 and \$24,517, respectively.

### Benefit Payments

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid in the following years:

	Defined Benefit Pension Plans	Postretirement Benefit Plans
<b>Year Ending August 31,</b>		
2025	\$ 113,589	\$ 35,202
2026	118,657	37,812
2027	123,929	40,473
2028	128,965	43,408
2029	133,544	46,213
2030-2034	726,829	269,605

### Multi-Employer Benefit Plans

NYU participates in multi-employer defined benefit pension plans. NYU makes cash contributions to these plans under the terms of collective-bargaining agreements that cover its union employees based on a fixed rate and hours worked per week by the covered employees. The risks of participating in these multi-employer plans are different from other single-employer plans in the following aspects: (1) assets contributed to the multi-employer plan by one employer may be used to provide benefits to employees of other participating employers; (2) if a participating employer

# New York University

## Notes to Consolidated Financial Statements

### August 31, 2024 and 2023

(in thousands of dollars)

stops contributing to the plan, the unfunded obligations of the plan may be borne by the remaining participating employers; and (3) if NYU chooses to stop participating in some of its multi-employer plans, NYU may be required to pay those plans an amount based on the underfunded status of the plan, referred to as a withdrawal liability.

NYU's contributions to the following multi-employer defined benefit pension and postretirement plans are reported as salary and fringe expenses in the consolidated statements of activities for the years ended August 31, 2024 and 2023:

	2024	2023
1199 SEIU Health Care Employees Health & Welfare Fund	\$ 198,060	\$ 169,469
1199 SEIU Health Care Employees Pension Fund	73,897	64,593
United Federation of Teachers Welfare Fund	24,274	19,758
Local 810 United Wire, Metal & Machine Health & Welfare Fund	5,842	5,579
Local 810 United Wire, Metal & Machine Pension Fund	4,138	3,873
Local 202 Health and Welfare Fund	1,901	1,342
Local 32B Pension Fund	922	425
Local 30 Health and Welfare	479	662
Local 30 Pension Fund	267	254
Local 153 Pension Fund	80	54
	<u>\$ 309,860</u>	<u>\$ 266,009</u>

NYU is in withdrawal status for the Local 153 Pension Fund with quarterly withdrawal payments continuing through 2033.

The Pension Protection Act zone status indicates a pension plan's funded status of either at least 80% funded (green) or less than 80% funded (yellow or red). A zone status of red requires the pension plan sponsor to implement a Funding Improvement Plan (FIP) or Rehabilitation Plan (RP). The following table includes information for the 1199 and Local 810 pension funds for the plan years ended December 31, 2023 and 2022.

Pension Plan Name	EIN/Pension Plan Number	Pension Protection Act Zone Status		FIP/RP Status Pending/ Implemented	Surcharge Imposed	Expiration Date of Collective-Bargaining Agreement
		2023	2022			
1199 Pension Fund	13-3604862	Green	Green	N/A	No	September 2026
Local 810 United Wire Pension Fund	13-6596940	Red	Red	Yes	Yes	June 2029

NYU's contributions to the 1199 Pension Fund and Local 810 United Wire Pension Fund represent greater than 5% of the respective total plan contributions based on the most recent IRS Form 5500s available.



**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

**15. Hospital Affiliations**

NYUGSoM has a master affiliation and three supplemental affiliation agreements with the New York City Health and Hospitals Corporation to provide general care and mental health services. The three supplemental agreements are with Woodhull Medical and Mental Health Center and Cumberland Diagnostic and Treatment Center, Bellevue Hospital Center and Gouverneur Healthcare Services, and Coler Rehabilitation and Nursing Care Center and Henry J. Carter Specialty Hospital and Nursing Facility. The current master affiliation agreement covers the period July 1, 2021 through June 30, 2025. NYUGSoM recognized revenues from these affiliation agreements of \$490,880 and \$454,582 for the years ended August 31, 2024 and 2023, respectively.

NYU Langone Hospitals has several clinical affiliation agreements with New York City area hospitals where physicians provide patient care and supervision of residents at affiliated organizations. NYU Langone Hospitals also maintains an affiliation agreement with Sunset Park Health Council, Inc., a New York not-for-profit corporation, d/b/a Family Health Centers at NYU Langone. NYU Langone Hospitals recognized revenue from these affiliation agreements of \$29,783 and \$25,352 for the years ended August 31, 2024 and 2023, respectively.

**16. Functional Classification of Expenses**

NYU's primary program services are instruction, research and patient care. NYU's additional program services are student services and libraries and auxiliary enterprises. Expenses reported as institutional services are incurred in support of one or more of NYU's program services. Natural expenses attributed to more than one functional expense category are allocated using a variety of cost allocation techniques such as square footage and time and effort.

Expenses by functional classification for the years ended August 31, 2024 and 2023 consist of the following:

	2024						
	Instruction and Other Academic Programs	Research and Other Sponsored Programs	Patient Care	Student Services and Libraries	Auxiliary Enterprises	Institutional Services	Total
Salaries and fringe	\$ 1,637,813	\$ 666,425	\$ 6,832,495	\$ 163,927	\$ 84,055	\$ 1,314,082	\$ 10,698,797
Medical and pharmaceutical costs	85	835	2,111,541	45	-	2,717	2,115,223
Professional services	129,405	36,561	385,302	24,763	72,302	277,841	926,174
Facilities costs	134,593	110,983	418,826	19,690	214,095	120,262	1,018,449
Fees, insurance and taxes	9,593	571	160,002	2,474	15,263	127,402	315,305
Depreciation and amortization	100,396	131,732	523,156	29,339	129,529	214,694	1,128,846
Interest	79,902	29,314	180,289	6,943	50,962	26,810	374,220
Other	233,357	363,121	226,306	73,768	21,211	351,241	1,269,004
	<u>\$ 2,325,144</u>	<u>\$ 1,339,542</u>	<u>\$ 10,837,917</u>	<u>\$ 320,949</u>	<u>\$ 587,417</u>	<u>\$ 2,435,049</u>	<u>\$ 17,846,018</u>
University	\$ 2,247,894	\$ 363,397	\$ 58,054	\$ 300,228	\$ 533,397	\$ 721,286	\$ 4,224,256
NYU Langone Health	<u>77,250</u>	<u>976,145</u>	<u>10,779,863</u>	<u>20,721</u>	<u>59,518</u>	<u>1,724,885</u>	<u>13,638,382</u>
	<u>\$ 2,325,144</u>	<u>\$ 1,339,542</u>	<u>\$ 10,837,917</u>	<u>\$ 320,949</u>	<u>\$ 592,915</u>	<u>\$ 2,446,171</u>	<u>17,862,638</u>
						Eliminations	(16,620)
							<u>\$ 17,846,018</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

	2023						
	Instruction and Other Academic Programs	Research and Other Sponsored Programs	Patient Care	Student Services and Libraries	Auxiliary Enterprises	Institutional Services	Total
Salaries and fringe	\$ 1,549,535	\$ 675,903	\$ 5,907,093	\$ 160,349	\$ 72,108	\$ 1,088,015	\$ 9,453,003
Medical and pharmaceutical costs	68	2,242	1,753,875	14	-	3,795	1,759,994
Professional services	127,321	40,022	310,380	24,596	79,356	227,029	808,704
Facilities costs	124,373	128,925	401,263	16,186	181,037	95,602	947,386
Fees, insurance and taxes	9,822	569	132,745	1,919	15,004	141,456	301,515
Depreciation and amortization	97,578	35,475	454,826	22,486	118,156	283,924	1,012,445
Interest	97,728	9,013	153,034	7,299	39,407	65,915	372,396
Other	243,499	358,213	293,311	69,592	19,500	271,150	1,255,265
	<u>\$ 2,249,924</u>	<u>\$ 1,250,362</u>	<u>\$ 9,406,527</u>	<u>\$ 302,441</u>	<u>\$ 524,568</u>	<u>\$ 2,176,886</u>	<u>\$ 15,910,708</u>
University	\$ 2,169,602	\$ 328,677	\$ 58,184	\$ 282,538	\$ 476,602	\$ 642,024	\$ 3,957,627
NYU Langone Health	80,322	921,685	9,348,343	19,903	52,704	1,542,949	11,965,906
	<u>\$ 2,249,924</u>	<u>\$ 1,250,362</u>	<u>\$ 9,406,527</u>	<u>\$ 302,441</u>	<u>\$ 529,306</u>	<u>\$ 2,184,973</u>	<u>15,923,533</u>
						Eliminations	(12,825)
							<u>\$ 15,910,708</u>

**17. Components of Net Assets with Donor Restrictions**

Net assets with donor restrictions are available for the following purposes at August 31, 2024 and 2023:

	2024	2023
Contributions and earnings for operating purposes	\$ 1,973,420	\$ 1,712,629
Scholarships and fellowships	1,886,605	1,628,582
Faculty and staff salaries	882,498	879,906
Program support	694,534	657,485
Annuity trust agreements	42,545	38,919
Contributions for buildings and equipment	7,406	8,159
Other	106,146	110,431
Total net assets with donor restrictions	<u>\$ 5,593,154</u>	<u>\$ 5,036,111</u>

NYU's investment pools include individual endowed funds established for a variety of purposes. Pooled assets include both donor restricted endowment funds and funds designated by the board to function as endowments.

NYU classifies as net assets with donor restrictions the historical value of donor-restricted endowment funds, which includes: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment required by the applicable donor gift instrument. Also included in net assets with donor restrictions is accumulated unspent earnings on donor restricted endowment funds which are available for expenditure in a manner consistent with the standard of prudence described by the New York Prudent Management of Institutional Funds Act (NYPMIFA), and deficiencies associated with funds where the value of the fund has fallen below the original value of the gift. The historical value of NYU's donor-restricted endowment funds totaled \$3,102,031 and \$2,954,093 at August 31, 2024 and 2023, respectively.

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

(in thousands of dollars)

NYU defines the appropriation of endowment net assets for expenditure as the authorization of its investment spending rate as approved annually by the Board of Trustees (Note 5). However, when donors have expressly stipulated the payout percentage of earnings on endowments that differs from NYU policies, the donors' intent prevails. In making a determination to appropriate or accumulate, NYU adheres to the standard of prudence prescribed by NYPMIFA and considers the following factors: the duration and preservation of the endowment fund; NYU's mission and the purpose of the endowment fund; general economic conditions; the possible effect of inflation or deflation; the expected total return from income and the appreciation of investments; other resources of NYU; where appropriate and circumstances would otherwise warrant, alternatives to expenditures of the endowment fund giving due consideration to the effect that such alternatives may have on NYU; and the investment policy of NYU.

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor required to be retained as a fund of perpetual duration. Deficiencies of this nature are reported in net assets with donor restrictions. As of August 31, 2024 and 2023, 6 funds and 34 funds, respectively, with original gift values of \$272 and \$14,899 were underwater by \$28 and \$302.

All endowment funds included within net assets without donor restrictions are board-designated. The following table provides the changes in the net asset classes of NYU's endowment funds at August 31:

	2024		
	Without Donor Restrictions	With Donor Restrictions	Total
<b>Investment pool net assets, beginning of year</b>	\$ 1,931,507	\$ 3,967,460	\$ 5,898,967
Contributions and transfers	207,737	42,499	250,236
Investment pool return	300,938	588,346	889,284
Endowment distribution	(84,213)	(169,548)	(253,761)
Liquidations	(38,919)	(2,467)	(41,386)
<b>Investment pool net assets, end of year</b>	<u>\$ 2,317,050</u>	<u>\$ 4,426,290</u>	<u>\$ 6,743,340</u>
	2023		
	Without Donor Restrictions	With Donor Restrictions	Total
<b>Investment pool net assets, beginning of year</b>	\$ 1,712,150	\$ 3,585,236	\$ 5,297,386
Contributions and transfers	139,107	239,395	378,502
Investment pool return	157,648	306,758	464,406
Endowment distribution	(73,286)	(155,617)	(228,903)
Liquidations	(4,112)	(8,312)	(12,424)
<b>Investment pool net assets, end of year</b>	<u>\$ 1,931,507</u>	<u>\$ 3,967,460</u>	<u>\$ 5,898,967</u>

**New York University**  
**Notes to Consolidated Financial Statements**  
**August 31, 2024 and 2023**

---

*(in thousands of dollars)*

**18. Commitments and Contingencies**

NYU has ongoing construction projects with contractual commitments totaling \$399,992 at August 31, 2024.

NYU is self-insured for workers' compensation. The University purchases an excess workers' compensation insurance policy with a retention of \$500 per claim and has maintained a surety bond in the amount of \$10,526 at August 31, 2024 and 2023. Additionally, NYU Langone Health has maintained stand-by letters of credit aggregating approximately \$100,347 and \$89,389 at August 31, 2024 and 2023, respectively.

In November 2023, the Centers for Medicare and Medicaid Services issued a final rule outlining the remedy for the invalidated Outpatient Prospective Payment System 340B-acquired drug payment policy for calendar years 2018 through 2022. As part of this rule, NYU Langone Hospitals received \$122,246 in full satisfaction of the underpayments related to those years, which was recorded within proceeds from settlements on the consolidated statement of activities for the year ended August 31, 2024.

In 2015, NYU Langone Health initiated lawsuits against a construction contractor for damages to property and business interruption arising from Superstorm Sandy in 2012. The litigation was resolved in March 2023 through an agreement in settlement of all claims, pursuant to which NYU Langone Hospitals received \$508,000, specifically for unrecovered business interruption losses. These proceeds were recorded within proceeds from settlements on the consolidated statement of activities for the year ended August 31, 2023.

NYU is a defendant in various legal actions arising from the normal course of its activities and amounts expended under government grants and contracts are subject to audit by governmental agencies. In addition, amounts received for patient care from Medicare and Medicaid are subject to audit. Although the final outcome of such actions and audits cannot be determined, management believes that eventual liability, if any, will not have a material effect on NYU's consolidated balance sheets.

**19. Subsequent Events**

NYU performed an evaluation of subsequent events through December 12, 2024, which is the date the consolidated financial statements were issued.

In October 2024, NYU Langone Hospitals issued, through DASNY, Series 2024A tax-exempt bonds totaling \$121,400. The Series 2024A bonds mature serially from July 2026 through July 2036 at a fixed rate of 5.00%. The proceeds of the Series 2024A bonds were used to advance refund the Series 2014 bonds and the Nassau County Local Economic Assistance Corporation bonds.

**Appendix A**  
**Supplemental Information**

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Summary)**  
**August 31, 2024**

	2024			
	University	NYU Langone Health	Eliminations	Consolidated NYU
<i>(in thousands of dollars)</i>				
<b>Assets</b>				
Cash and cash equivalents	\$ 1,226,154	\$ 1,621,379	\$ -	\$ 2,847,533
Short-term investments (Note 5)	14,659	810,800	-	825,459
Accounts and loans receivable, net (Note 6)	386,627	421,780	(93,611)	714,796
Patient accounts receivable, net (Note 4)	10,123	1,532,383	-	1,542,506
Contributions receivable, net (Note 7)	219,181	436,295	-	655,476
Other assets (Note 8)	377,638	1,010,372	-	1,388,010
Deposits with trustees (Note 9)	61,232	53,467	-	114,699
Long-term investments (Note 5)	5,225,711	2,616,253	-	7,841,964
Operating right-of-use assets (Note 11)	484,239	1,572,334	-	2,056,573
Assets held for professional liabilities (Note 13)	-	1,302,614	-	1,302,614
Land, buildings, and equipment, net (Note 10)	5,477,243	9,718,126	-	15,195,369
Total assets	<u>\$ 13,482,807</u>	<u>\$ 21,095,803</u>	<u>\$ (93,611)</u>	<u>\$ 34,484,999</u>
<b>Liabilities and Net Assets</b>				
<b>Liabilities</b>				
Accounts payable and accrued expenses	\$ 504,605	\$ 2,319,888	\$ (93,611)	\$ 2,730,882
Deferred revenue	1,232,731	71,677	-	1,304,408
Operating lease liability (Note 11)	519,963	1,743,553	-	2,263,516
Professional liabilities (Note 13)	-	1,032,601	-	1,032,601
Debt and other obligations (Note 12)	4,130,160	5,529,525	-	9,659,685
Funds held for others (Notes 6 and 8)	167,625	523,332	-	690,957
Accrued benefit obligation (Note 14)	-	231,847	-	231,847
Accrued postretirement obligation (Note 14)	354,099	125,855	-	479,954
Asset retirement obligation	219,763	104,152	-	323,915
Total liabilities	<u>7,128,946</u>	<u>11,682,430</u>	<u>(93,611)</u>	<u>18,717,765</u>
<b>Net assets</b>				
Without donor restrictions	2,713,263	7,458,117	2,700	10,174,080
With donor restrictions (Note 17)	3,640,598	1,955,256	(2,700)	5,593,154
Total net assets	<u>6,353,861</u>	<u>9,413,373</u>	<u>-</u>	<u>15,767,234</u>
Total liabilities and net assets	<u>\$ 13,482,807</u>	<u>\$ 21,095,803</u>	<u>\$ (93,611)</u>	<u>\$ 34,484,999</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Summary)**  
**August 31, 2023**

	2023			
	University	NYU Langone Health	Eliminations	Consolidated NYU
<i>(in thousands of dollars)</i>				
<b>Assets</b>				
Cash and cash equivalents	\$ 986,758	\$ 403,339	\$ -	\$ 1,390,097
Short-term investments (Note 5)	257,619	2,116,075	-	2,373,694
Accounts and loans receivable, net (Note 6)	429,183	388,859	(84,962)	733,080
Patient accounts receivable, net (Note 4)	7,235	1,223,088	-	1,230,323
Contributions receivable, net (Note 7)	226,896	467,753	-	694,649
Other assets (Note 8)	320,506	919,244	-	1,239,750
Deposits with trustees (Note 9)	214,220	130,148	-	344,368
Long-term investments (Note 5)	4,591,720	2,220,385	-	6,812,105
Operating right-of-use assets (Note 11)	543,129	1,497,096	-	2,040,225
Assets held for professional liabilities (Note 13)	-	1,096,600	-	1,096,600
Land, buildings, and equipment, net (Note 10)	5,196,180	9,323,599	-	14,519,779
Total assets	<u>\$ 12,773,446</u>	<u>\$ 19,786,186</u>	<u>\$ (84,962)</u>	<u>\$ 32,474,670</u>
<b>Liabilities and Net Assets</b>				
<b>Liabilities</b>				
Accounts payable and accrued expenses	\$ 499,836	\$ 2,160,818	\$ (84,962)	\$ 2,575,692
Deferred revenue	1,263,145	74,610	-	1,337,755
Operating lease liability (Note 11)	578,506	1,647,856	-	2,226,362
Professional liabilities (Note 13)	-	967,037	-	967,037
Debt and other obligations (Note 12)	3,981,161	5,687,107	-	9,668,268
Funds held for others (Notes 6 and 8)	144,389	408,155	-	552,544
Accrued benefit obligation (Note 14)	-	229,087	-	229,087
Accrued postretirement obligation (Note 14)	283,366	173,451	-	456,817
Asset retirement obligation	214,005	87,938	-	301,943
Total liabilities	<u>6,964,408</u>	<u>11,436,059</u>	<u>(84,962)</u>	<u>18,315,505</u>
<b>Net assets</b>				
Without donor restrictions	2,555,388	6,567,666	-	9,123,054
With donor restrictions (Note 17)	3,253,650	1,782,461	-	5,036,111
Total net assets	<u>5,809,038</u>	<u>8,350,127</u>	<u>-</u>	<u>14,159,165</u>
Total liabilities and net assets	<u>\$ 12,773,446</u>	<u>\$ 19,786,186</u>	<u>\$ (84,962)</u>	<u>\$ 32,474,670</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Detail)**  
**August 31, 2024**

	2024						
(in thousands of dollars)	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	Total Consolidated NYU
<b>Assets</b>							
Cash and cash equivalents	\$ 1,226,154	\$ 48,066	\$ -	\$ 1,274,220	\$ 1,573,313	\$ -	\$ 2,847,533
Short-term investments (Note 5)	14,659	-	-	14,659	810,800	-	825,459
Accounts and loans receivable, net (Note 6)	386,627	226,970	(72,684)	540,913	319,012	(145,129)	714,796
Patient accounts receivable, net (Note 4)	10,123	191,104	-	201,227	1,341,279	-	1,542,506
Contributions receivable, net (Note 7)	219,181	126,607	-	345,788	309,688	-	655,476
Other assets (Note 8)	377,638	523,064	-	900,702	487,308	-	1,388,010
Deposits with trustees (Note 9)	61,232	-	-	61,232	53,467	-	114,699
Long-term investments (Note 5)	5,225,711	1,487,017	-	6,712,728	1,129,236	-	7,841,964
Operating right-of-use assets (Note 11)	484,239	1,085,509	-	1,569,748	486,825	-	2,056,573
Assets held for professional liabilities (Note 13)	-	-	-	-	1,302,614	-	1,302,614
Land, buildings, and equipment, net (Note 10)	5,477,243	4,185,782	-	9,663,025	5,532,344	-	15,195,369
Total assets	<u>\$ 13,482,807</u>	<u>\$ 7,874,119</u>	<u>\$ (72,684)</u>	<u>\$ 21,284,242</u>	<u>\$ 13,345,886</u>	<u>\$ (145,129)</u>	<u>\$ 34,484,999</u>
<b>Liabilities and Net Assets</b>							
<b>Liabilities</b>							
Accounts payable and accrued expenses	\$ 504,605	\$ 930,936	\$ (72,684)	\$ 1,362,857	\$ 1,513,154	\$ (145,129)	\$ 2,730,882
Deferred revenue	1,232,731	54,900	-	1,287,631	16,777	-	1,304,408
Operating lease liability (Note 11)	519,963	1,198,420	-	1,718,383	545,133	-	2,263,516
Professional liabilities (Note 13)	-	-	-	-	1,032,601	-	1,032,601
Debt and other obligations (Note 12)	4,130,160	2,332,906	-	6,463,066	3,196,619	-	9,659,685
Funds held for others (Notes 6 and 8)	167,625	463,679	-	631,304	59,653	-	690,957
Accrued benefit obligation (Note 14)	-	-	-	-	231,847	-	231,847
Accrued postretirement obligation (Note 14)	354,099	72,444	-	426,543	53,411	-	479,954
Asset retirement obligation	219,763	27,677	-	247,440	76,475	-	323,915
Total liabilities	<u>7,128,946</u>	<u>5,080,962</u>	<u>(72,684)</u>	<u>12,137,224</u>	<u>6,725,670</u>	<u>(145,129)</u>	<u>18,717,765</u>
<b>Net assets</b>							
Without donor restrictions	2,713,263	1,367,942	2,700	4,083,905	6,090,175	-	10,174,080
With donor restrictions (Note 17)	3,640,598	1,425,215	(2,700)	5,063,113	530,041	-	5,593,154
Total net assets	<u>6,353,861</u>	<u>2,793,157</u>	<u>-</u>	<u>9,147,018</u>	<u>6,620,216</u>	<u>-</u>	<u>15,767,234</u>
Total liabilities and net assets	<u>\$ 13,482,807</u>	<u>\$ 7,874,119</u>	<u>\$ (72,684)</u>	<u>\$ 21,284,242</u>	<u>\$ 13,345,886</u>	<u>\$ (145,129)</u>	<u>\$ 34,484,999</u>

The accompanying note is an integral part of these supplemental schedules.



**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Balance Sheet for NYU - Detail)**  
**August 31, 2023**

	2023						
	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	Total Consolidated NYU
<i>(in thousands of dollars)</i>							
<b>Assets</b>							
Cash and cash equivalents	\$ 986,758	\$ 58,764	\$ -	\$ 1,045,522	\$ 344,575	\$ -	\$ 1,390,097
Short-term investments (Note 5)	257,619	-	-	257,619	2,116,075	-	2,373,694
Accounts and loans receivable, net (Note 6)	429,183	210,923	(68,943)	571,163	386,557	(224,640)	733,080
Patient accounts receivable, net (Note 4)	7,235	157,965	-	165,200	1,065,123	-	1,230,323
Contributions receivable, net (Note 7)	226,896	108,041	-	334,937	359,712	-	694,649
Other assets (Note 8)	320,506	461,709	-	782,215	457,535	-	1,239,750
Deposits with trustees (Note 9)	214,220	-	-	214,220	130,148	-	344,368
Long-term investments (Note 5)	4,591,720	1,291,554	-	5,883,274	928,831	-	6,812,105
Operating right-of-use assets (Note 11)	543,129	984,405	-	1,527,534	512,691	-	2,040,225
Assets held for professional liabilities (Note 13)	-	-	-	-	1,096,600	-	1,096,600
Land, buildings, and equipment, net (Note 10)	5,196,180	3,979,446	-	9,175,626	5,344,153	-	14,519,779
Total assets	<u>\$ 12,773,446</u>	<u>\$ 7,252,807</u>	<u>\$ (68,943)</u>	<u>\$ 19,957,310</u>	<u>\$ 12,742,000</u>	<u>\$ (224,640)</u>	<u>\$ 32,474,670</u>
<b>Liabilities and Net Assets</b>							
<b>Liabilities</b>							
Accounts payable and accrued expenses	\$ 499,836	\$ 997,368	\$ (68,943)	\$ 1,428,261	\$ 1,372,071	\$ (224,640)	\$ 2,575,692
Deferred revenue	1,263,145	54,528	-	1,317,673	20,082	-	1,337,755
Operating lease liability (Note 11)	578,506	1,077,269	-	1,655,775	570,587	-	2,226,362
Professional liabilities (Note 13)	-	-	-	-	967,037	-	967,037
Debt and other obligations (Note 12)	3,981,161	2,427,998	-	6,409,159	3,259,109	-	9,668,268
Funds held for others (Notes 6 and 8)	144,389	360,756	-	505,145	47,399	-	552,544
Accrued benefit obligation (Note 14)	-	-	-	-	229,087	-	229,087
Accrued postretirement obligation (Note 14)	283,366	99,268	-	382,634	74,183	-	456,817
Asset retirement obligation	214,005	28,326	-	242,331	59,612	-	301,943
Total liabilities	<u>6,964,408</u>	<u>5,045,513</u>	<u>(68,943)</u>	<u>11,940,978</u>	<u>6,599,167</u>	<u>(224,640)</u>	<u>18,315,505</u>
<b>Net assets</b>							
Without donor restrictions	2,555,388	954,404	-	3,509,792	5,613,262	-	9,123,054
With donor restrictions (Note 17)	3,253,650	1,252,890	-	4,506,540	529,571	-	5,036,111
Total net assets	<u>5,809,038</u>	<u>2,207,294</u>	<u>-</u>	<u>8,016,332</u>	<u>6,142,833</u>	<u>-</u>	<u>14,159,165</u>
Total liabilities and net assets	<u>\$ 12,773,446</u>	<u>\$ 7,252,807</u>	<u>\$ (68,943)</u>	<u>\$ 19,957,310</u>	<u>\$ 12,742,000</u>	<u>\$ (224,640)</u>	<u>\$ 32,474,670</u>

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Summary)**  
**Year Ended August 31, 2024**

	2024			
	University	NYU Langone Health	Eliminations	Consolidated NYU
(in thousands of dollars)				
Changes in net assets without donor restrictions				
Operating revenues				
Tuition and fees (net of financial aid awards of \$895,575 University; \$31,082 NYU Langone Health)	\$ 2,518,104	\$ 48,745	\$ -	\$ 2,566,849
Grants and contracts (Note 2)	790,277	794,072	-	1,584,349
Patient care (Note 4)	54,350	11,059,864	-	11,114,214
Pharmacy revenue	-	870,909	-	870,909
Hospital affiliations (Note 15)	-	520,663	-	520,663
Insurance premiums earned	-	27,692	-	27,692
Contributions	50,493	47,796	-	98,289
Endowment distribution (Note 5)	199,588	54,173	-	253,761
Return on short-term investments (Note 5)	71,001	148,074	-	219,075
Auxiliary enterprises (net of financial aid awards of \$94,505)	393,038	64,064	(5,498)	451,604
Program fees and other	108,094	228,140	(8,422)	327,812
Net assets released from restrictions	108,206	98,251	-	206,457
Total operating revenues	4,293,151	13,962,443	(13,920)	18,241,674
Expenses (Note 16)				
Salaries and fringe	2,468,909	8,229,888	-	10,698,797
Medical and pharmaceutical costs	-	2,115,223	-	2,115,223
Professional services	336,838	589,336	-	926,174
Facilities costs	401,117	622,830	(5,498)	1,018,449
Fees, insurance and taxes	71,147	244,158	-	315,305
Depreciation and amortization	305,171	823,675	-	1,128,846
Interest	152,584	221,636	-	374,220
Other	488,490	791,636	(11,122)	1,269,004
Total expenses	4,224,256	13,638,382	(16,620)	17,846,018
Excess of operating revenues over expenses	68,895	324,061	2,700	395,656
Nonoperating activities				
Investment return (Note 5)	256,518	332,519	-	589,037
Appropriation of endowment distribution (Note 5)	(72,737)	(11,476)	-	(84,213)
Pension and postretirement nonservice costs (Note 14)	(9,797)	24,386	-	14,589
Changes in pension and postretirement obligations (Note 14)	(71,805)	13,171	-	(58,634)
Net assets released from restrictions for capital	-	38,726	-	38,726
Proceeds from settlements (Note 18)	-	122,246	-	122,246
Other	(13,199)	46,818	-	33,619
Increase in net assets without donor restrictions	157,875	890,451	2,700	1,051,026
Changes in net assets with donor restrictions				
Contributions	205,600	178,958	(2,700)	381,858
Investment return (Note 5)	418,491	173,240	-	591,731
Appropriation of endowment distribution (Note 5)	(126,851)	(42,697)	-	(169,548)
Other	(2,086)	271	-	(1,815)
Net assets released from restrictions	(108,206)	(136,977)	-	(245,183)
Increase in net assets with donor restrictions	386,948	172,795	(2,700)	557,043
Increase in net assets	\$ 544,823	\$ 1,063,246	\$ -	\$ 1,608,069

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Summary)**  
**Year Ended August 31, 2023**

	2023			Consolidated NYU
	University	NYU Langone Health	Eliminations	
(in thousands of dollars)				
<b>Changes in net assets without donor restrictions</b>				
Operating revenues				
Tuition and fees (net of financial aid awards of \$869,082 University; \$28,846 NYU Langone Health)	\$ 2,465,425	\$ 45,864	\$ -	\$ 2,511,289
Grants and contracts (Note 2)	761,334	761,155	-	1,522,489
Patient care (Note 4)	51,770	9,779,562	-	9,831,332
Pharmacy Revenue	-	686,810	-	686,810
Hospital affiliations (Note 15)	-	479,934	-	479,934
Insurance premiums earned	-	27,555	-	27,555
Contributions	43,674	33,763	-	77,437
Endowment distribution (Note 5)	177,125	51,778	-	228,903
Return on short-term investments (Note 5)	51,045	113,314	-	164,359
Auxiliary enterprises (net of financial aid awards of \$91,060)	371,774	50,331	(4,738)	417,367
Program fees and other	125,006	198,845	(8,087)	315,764
Net assets released from restrictions	99,962	65,334	-	165,296
Total operating revenues	4,147,115	12,294,245	(12,825)	16,428,535
Expenses (Note 16)				
Salaries and fringe	2,300,619	7,152,384	-	9,453,003
Medical and pharmaceutical costs	-	1,759,994	-	1,759,994
Professional services	309,033	499,671	-	808,704
Facilities costs	387,805	564,319	(4,738)	947,386
Fees, insurance and taxes	64,107	237,408	-	301,515
Depreciation and amortization	285,058	727,387	-	1,012,445
Interest	153,009	219,387	-	372,396
Other	457,996	805,356	(8,087)	1,255,265
Total expenses	3,957,627	11,965,906	(12,825)	15,910,708
Excess of operating revenues over expenses	189,488	328,339	-	517,827
Nonoperating activities				
Investment return (Note 5)	167,130	162,705	-	329,835
Appropriation of endowment distribution (Note 5)	(62,510)	(10,776)	-	(73,286)
Pension and postretirement nonservice costs (Note 14)	(9,309)	28,179	-	18,870
Changes in pension and postretirement obligations (Note 14)	74,136	155,727	-	229,863
Net assets released from restrictions for capital	28	103,569	-	103,597
Proceeds from settlements (Note 18)	-	508,000	-	508,000
Other	(2,330)	1,438	-	(892)
Increase in net assets without donor restrictions	356,633	1,277,181	-	1,633,814
<b>Changes in net assets with donor restrictions</b>				
Contributions	168,593	283,359	-	451,952
Investment return (Note 5)	179,982	94,015	-	273,997
Appropriation of endowment distribution (Note 5)	(114,615)	(41,002)	-	(155,617)
Other	(2,652)	251	-	(2,401)
Net assets released from restrictions	(99,990)	(168,903)	-	(268,893)
Increase in net assets with donor restrictions	131,318	167,720	-	299,038
Increase in net assets	\$ 487,951	\$ 1,444,901	\$ -	\$ 1,932,852

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Detail)**  
**Year Ended August 31, 2024**

	2024						Total Consolidated NYU
(in thousands of dollars)	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	
<b>Changes in net assets without donor restrictions</b>							
Operating revenues							
Tuition and fees (net of financial aid awards of \$895,575 University; and \$31,082 NYU Langone Health)	\$ 2,518,104	\$ 48,503	\$ -	\$ 2,566,607	\$ 242	\$ -	\$ 2,566,849
Grants and contracts (Note 2)	790,277	785,833	-	1,576,110	8,239	-	1,584,349
Patient care (Note 4)	54,350	3,721,879	-	3,776,229	8,353,464	(1,015,479)	11,114,214
Pharmacy revenue	-	-	-	-	870,909	-	870,909
Hospital affiliations (Note 15)	-	490,880	-	490,880	29,783	-	520,663
Insurance premiums earned	-	-	-	-	131,382	(103,690)	27,692
Contributions	50,493	35,580	-	86,073	12,216	-	98,289
Endowment distribution (Note 5)	199,588	51,227	-	250,815	2,946	-	253,761
Return on short-term investments (Note 5)	71,001	137	-	71,138	147,937	-	219,075
Auxiliary enterprises (net of financial aid awards of \$94,505)	393,038	37,157	(5,498)	424,697	26,907	-	451,604
Program fees and other	108,094	735,862	(8,422)	835,534	193,188	(700,910)	327,812
Net assets released from restrictions	108,206	44,170	-	152,376	54,081	-	206,457
Total operating revenues	4,293,151	5,951,228	(13,920)	10,230,459	9,831,294	(1,820,079)	18,241,674
Expenses (Note 16)							
Salaries and fringe	2,468,909	4,520,426	-	6,989,335	3,753,354	(43,892)	10,698,797
Medical and pharmaceutical costs	-	112,840	-	112,840	2,002,383	-	2,115,223
Professional services	336,838	238,443	-	575,281	1,956,109	(1,605,216)	926,174
Facilities costs	401,117	352,064	(5,498)	747,683	270,766	-	1,018,449
Fees, insurance and taxes	71,147	121,701	-	192,848	226,147	(103,690)	315,305
Depreciation and amortization	305,171	329,509	-	634,680	494,166	-	1,128,846
Interest	152,584	96,092	-	248,676	125,544	-	374,220
Other	488,490	481,539	(11,122)	958,907	377,378	(67,281)	1,269,004
Total expenses	4,224,256	6,252,614	(16,620)	10,460,250	9,205,847	(1,820,079)	17,846,018
Excess (deficiency) of operating revenues over expenses	68,895	(301,386)	2,700	(229,791)	625,447	-	395,656
Nonoperating activities							
Investment return (Note 5)	256,518	43,094	-	299,612	289,425	-	589,037
Appropriation of endowment distribution (Note 5)	(72,737)	(11,005)	-	(83,742)	(471)	-	(84,213)
Pension and postretirement nonservice costs (Note 14)	(9,797)	(1,235)	-	(11,032)	25,621	-	14,589
Changes in pension and postretirement obligations (Note 14)	(71,805)	27,992	-	(43,813)	(14,821)	-	(58,634)
Net assets released from restrictions for capital	-	32,477	-	32,477	6,249	-	38,726
Proceeds from settlements (Note 18)	-	-	-	-	122,246	-	122,246
Other	(13,199)	573,601	-	560,402	(526,783)	-	33,619
Mission based payment	-	50,000	-	50,000	(50,000)	-	-
Increase in net assets without donor restrictions	157,875	413,538	2,700	574,113	476,913	-	1,051,026
<b>Changes in net assets with donor restrictions</b>							
Contributions	205,600	124,692	(2,700)	327,592	54,266	-	381,858
Investment return (Note 5)	418,491	159,166	-	577,657	14,074	-	591,731
Appropriation of endowment distribution (Note 5)	(126,851)	(40,222)	-	(167,073)	(2,475)	-	(169,548)
Other	(2,086)	5,336	-	3,250	(5,065)	-	(1,815)
Net assets released from restrictions	(108,206)	(76,647)	-	(184,853)	(60,330)	-	(245,183)
Increase in net assets with donor restrictions	386,948	172,325	(2,700)	556,573	470	-	557,043
Increase in net assets	\$ 544,823	\$ 585,863	\$ -	\$ 1,130,686	\$ 477,383	\$ -	\$ 1,608,069

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Activities for NYU - Detail)**  
**Year Ended August 31, 2023**

	2023						Total Consolidated NYU
(in thousands of dollars)	University	NYU Schools of Medicine	Eliminations	Subtotal	Health System	Eliminations	
<b>Changes in net assets without donor restrictions</b>							
Operating revenues							
Tuition and fees (net of financial aid awards of \$869,082 University; and \$28,846 NYU Langone Health)	\$ 2,465,425	\$ 45,622	\$ -	\$ 2,511,047	\$ 242	\$ -	\$ 2,511,289
Grants and contracts (Note 2)	761,334	756,228	-	1,517,562	4,927	-	1,522,489
Patient care (Note 4)	51,770	3,284,254	-	3,336,024	7,388,560	(893,252)	9,831,332
Pharmacy revenue	-	-	-	-	686,810	-	686,810
Hospital affiliations (Note 15)	-	454,582	-	454,582	25,352	-	479,934
Insurance premiums earned	-	-	-	-	117,784	(90,229)	27,555
Contributions	43,674	24,119	-	67,793	9,644	-	77,437
Endowment distribution (Note 5)	177,125	49,381	-	226,506	2,397	-	228,903
Return on short-term investments (Note 5)	51,045	489	-	51,534	112,825	-	164,359
Auxiliary enterprises (net of financial aid awards of \$91,060)	371,774	25,529	(4,738)	392,565	24,802	-	417,367
Program fees and other	125,006	516,978	(8,087)	633,897	196,228	(514,361)	315,764
Net assets released from restrictions	99,962	40,194	-	140,156	25,140	-	165,296
Total operating revenues	4,147,115	5,197,376	(12,825)	9,331,666	8,594,711	(1,497,842)	16,428,535
Expenses (Note 16)							
Salaries and fringe	2,300,619	3,885,936	-	6,186,555	3,309,777	(43,329)	9,453,003
Medical and pharmaceutical costs	-	98,661	-	98,661	1,661,333	-	1,759,994
Professional services	309,033	213,595	-	522,628	1,558,362	(1,272,286)	808,704
Facilities costs	387,805	313,094	(4,738)	696,161	251,225	-	947,386
Fees, insurance and taxes	64,107	117,667	-	181,774	209,970	(90,229)	301,515
Depreciation and amortization	285,058	264,522	-	549,580	462,865	-	1,012,445
Interest	153,009	93,841	-	246,850	125,546	-	372,396
Other	457,996	481,532	(8,087)	931,441	415,822	(91,998)	1,255,265
Total expenses	3,957,627	5,468,848	(12,825)	9,413,650	7,994,900	(1,497,842)	15,910,708
Excess (deficiency) of operating revenues over expenses	189,488	(271,472)	-	(81,984)	599,811	-	517,827
Nonoperating activities							
Investment return (Note 5)	167,130	24,376	-	191,506	138,329	-	329,835
Appropriation of endowment distribution (Note 5)	(62,510)	(10,602)	-	(73,112)	(174)	-	(73,286)
Pension and postretirement nonservice costs (Note 14)	(9,309)	4,542	-	(4,767)	23,637	-	18,870
Changes in pension and postretirement obligations (Note 14)	74,136	(1,411)	-	72,725	157,138	-	229,863
Net assets released from restrictions for capital	28	45,238	-	45,266	58,331	-	103,597
Proceeds from settlements (Note 18)	-	-	-	-	508,000	-	508,000
Other	(2,330)	284,943	-	282,613	(283,505)	-	(892)
Mission based payment	-	50,000	-	50,000	(50,000)	-	-
Increase in net assets without donor restrictions	356,633	125,614	-	482,247	1,151,567	-	1,633,814
<b>Changes in net assets with donor restrictions</b>							
Contributions	168,593	92,642	-	261,235	190,717	-	451,952
Investment return (Note 5)	179,982	86,875	-	266,857	7,140	-	273,997
Appropriation of endowment distribution (Note 5)	(114,615)	(38,779)	-	(153,394)	(2,223)	-	(155,617)
Other	(2,652)	(21,088)	-	(23,740)	21,339	-	(2,401)
Net assets released from restrictions	(99,990)	(85,432)	-	(185,422)	(83,471)	-	(268,893)
Increase in net assets with donor restrictions	131,318	34,218	-	165,536	133,502	-	299,038
Increase in net assets	\$ 487,951	\$ 159,832	\$ -	\$ 647,783	\$ 1,285,069	\$ -	\$ 1,932,852

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Cash Flows for NYU – Summary)**  
**Year Ended August 31, 2024**

	2024			
	University	NYU Langone Health	Eliminations	Consolidated NYU
<i>(in thousands of dollars)</i>				
<b>Cash flows from operating activities</b>				
Change in net assets	\$ 544,823	\$ 1,063,246	\$ -	\$ 1,608,069
Adjustments to reconcile change in net assets to net cash provided by operating activities				
Depreciation and amortization	305,171	823,675	-	1,128,846
Loss on sale or disposal of land, buildings and equipment	159	-	-	159
Net gain on investments, deposits with trustees and split-interest agreements	(653,392)	(456,627)	-	(1,110,019)
Bad debt expense	10,224	81,755	-	91,979
Pension and postretirement obligation change	71,805	(13,171)	-	58,634
Contributions received for permanent investment and capital	(84,065)	(75,946)	-	(160,011)
Amortization of operating right-of-use assets	112,933	161,048	-	273,981
Changes in operating assets and liabilities				
Decrease (increase) in accounts and loans receivable, net	33,757	(32,921)	8,649	9,485
Increase in patient accounts receivable	(2,888)	(309,295)	-	(312,183)
Decrease (increase) in contributions receivable	6,290	(50,297)	-	(44,007)
Increase in other assets	(10,280)	(26,686)	-	(36,966)
(Decrease) increase in asset retirement obligation	(5,502)	1,464	-	(4,038)
(Decrease) increase in accounts payable and accrued expenses	(10,504)	116,274	(8,649)	97,121
Decrease in operating lease liability	(112,586)	(140,589)	-	(253,175)
Increase in professional liabilities	-	65,564	-	65,564
Decrease in deferred revenue	(30,414)	(2,933)	-	(33,347)
Decrease in accrued benefit obligation	(11,823)	(32,216)	-	(44,039)
(Decrease) increase in accrued postretirement obligation	(3,384)	551	-	(2,833)
Net cash provided by operating activities	160,324	1,172,896	-	1,333,220
<b>Cash flows from investing activities</b>				
Purchases of investments	(1,138,324)	(4,790,192)	-	(5,928,516)
Sales and maturities of investments	1,432,687	5,850,689	-	7,283,376
Drawdowns of unexpended bond proceeds	160,602	-	-	160,602
Proceeds from sale of building	-	6,000	-	6,000
Additions to land, buildings, and equipment	(560,031)	(1,164,326)	-	(1,724,357)
Net cash used in investing activities	(105,066)	(97,829)	-	(202,895)
<b>Cash flows from financing activities</b>				
Contributions restricted for permanent investment and capital	84,065	75,946	-	160,011
Proceeds from short-term borrowings	355,200	-	-	355,200
Proceeds from finance lease incentives	-	4,408	-	4,408
Principal payments on long-term borrowings and finance leases	(111,936)	(113,585)	-	(225,521)
Line of credit repayments	(93,800)	-	-	(93,800)
Decrease in funds held for others	(3,327)	-	-	(3,327)
Net cash provided by (used in) financing activities	230,202	(33,231)	-	196,971
Net increase in cash, cash equivalents and restricted cash	285,460	1,041,836	-	1,327,296
<b>Cash, cash equivalents and restricted cash</b>				
Beginning of year	1,101,689	669,678	-	1,771,367
End of year	\$ 1,387,149	\$ 1,711,514	\$ -	\$ 3,098,663
<b>Supplemental disclosure of cash flow information</b>				
Interest paid	\$ 158,266	\$ 237,063	\$ -	\$ 395,329
Change in noncash acquisitions of land, buildings, and equipment	15,273	57,546	-	72,819
Right-of-use assets obtained				
In exchange for new operating lease obligations	38,711	269,011	-	307,722
In exchange for new finance lease obligations	20,101	60,782	-	80,883

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Supplemental Schedule to the Consolidated Financial Statements**  
**(Consolidating Statement of Cash Flows for NYU – Summary)**  
**Year Ended August 31, 2023**

	2023			
	University	NYU Langone Health	Eliminations	Consolidated NYU
<i>(in thousands of dollars)</i>				
<b>Cash flows from operating activities</b>				
Change in net assets	\$ 487,951	\$ 1,444,901	\$ -	\$ 1,932,852
Adjustments to reconcile change in net assets to net cash provided by operating activities				
Depreciation and amortization	285,058	727,387	-	1,012,445
Gain on sale or disposal of land, buildings and equipment	(7,236)	(113)	-	(7,349)
Net gain on investments, deposits with trustees and split-interest agreements	(314,842)	(220,021)	-	(534,863)
Bad debt expense	7,543	419	-	7,962
Pension and postretirement obligation change	(74,136)	(155,727)	-	(229,863)
Contributions received for permanent investment and capital	(87,836)	(42,932)	-	(130,768)
Proceeds from disaster recovery award for hazard mitigation and capital	-	(13,264)	-	(13,264)
Amortization of operating right-of-use assets	113,164	159,642	-	272,806
Changes in operating assets and liabilities				
(Increase) decrease in accounts and loans receivable, net	(12,985)	6,535	13,884	7,434
Increase in patient accounts receivable	(101)	(14,502)	-	(14,603)
Decrease (increase) in contributions receivable	42,780	(116,512)	-	(73,732)
Increase in other assets	(3,712)	(83,100)	-	(86,812)
(Decrease) increase in asset retirement obligation	(1,410)	84	-	(1,326)
(Decrease) increase in accounts payable and accrued expenses	(40,445)	64,204	(13,884)	9,875
Decrease in operating lease liability	(110,994)	(141,431)	-	(252,425)
Increase in professional liabilities	-	49,809	-	49,809
Increase in deferred revenue	17,254	20,636	-	37,890
Decrease in accrued benefit obligation	(10,364)	(4,978)	-	(15,342)
(Decrease) increase in accrued postretirement obligation	(286)	4,057	-	3,771
Net cash provided by operating activities	289,403	1,685,094	-	1,974,497
<b>Cash flows from investing activities</b>				
Purchases of investments	(1,573,587)	(3,518,185)	-	(5,091,772)
Sales and maturities of investments	1,333,413	1,795,040	-	3,128,453
Drawdowns of unexpended bond proceeds	121,034	-	-	121,034
Additions to land, buildings, and equipment	(522,744)	(1,128,871)	-	(1,651,615)
Net cash used in investing activities	(641,884)	(2,852,016)	-	(3,493,900)
<b>Cash flows from financing activities</b>				
Contributions restricted for permanent investment and capital	87,836	42,932	-	130,768
Proceeds from disaster recovery award for hazard mitigation and capital	-	13,264	-	13,264
Proceeds from finance lease incentives	-	15,077	-	15,077
Principal payments on long-term borrowings and finance leases	(107,613)	(114,271)	-	(221,884)
Decrease in funds held for others	(19,781)	-	-	(19,781)
Net cash used in financing activities	(39,558)	(42,998)	-	(82,556)
Net decrease in cash, cash equivalents and restricted cash	(392,039)	(1,209,920)	-	(1,601,959)
<b>Cash, cash equivalents and restricted cash</b>				
Beginning of year	1,493,728	1,879,598	-	3,373,326
End of year	\$ 1,101,689	\$ 669,678	\$ -	\$ 1,771,367
<b>Supplemental disclosure of cash flow information</b>				
Interest paid	\$ 158,532	\$ 231,522	\$ -	\$ 390,054
Change in noncash acquisitions of land, buildings, and equipment	32,113	115,342	-	147,455
Right-of-use assets obtained				
In exchange for new operating lease obligations	55,260	149,755	-	205,015
In exchange for new finance lease obligations	-	233,624	-	233,624

The accompanying note is an integral part of these supplemental schedules.

**New York University**  
**Note to Consolidating Supplemental Schedules**  
**August 31, 2024 and 2023**

---

**1. Basis of Presentation – Consolidating Supplemental Schedules**

The consolidating supplemental schedules (consolidating information) presented on pages 43-52 was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, changes in net assets and cash flows of the individual companies within NYU and is not a required part of the consolidated financial statements. The individual reporting entities within NYU as presented within the consolidating information are disclosed within Note 1 to the consolidated financial statements.

The consolidating financial statements were prepared on an accrual basis of accounting, consistent with the consolidated financial statements (Note 2). All transactions between and amounts due to (from) the reporting entities within NYU have been eliminated within the consolidating supplemental schedules.